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Transcriptional regulation of sonic hedgehog target genes in the 
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Jordan Paul Lewandowski, Ph.D. 
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Supervisor:  Steven A. Vokes 
 
The Hedgehog (HH) family of secreted proteins are critical regulators of embryonic 
development. Dysregulation of the HH pathway results in a large class of developmental 
defects as well as several types of cancer. HH signaling elicits a transcriptional response 
by regulating GLI transcription factors. The mechanisms by which GLIs activate and 
sustain gene expression in response to HH are not well understood. To address this in the 
limb, we undertook a systems level analysis to determine the spatiotemporal kinetics of the 
GLI transcriptional response. In addition, we focus on the regulation of a single GLI-bound 
cis-regulatory module (CRM) associated with the GLI target gene, Gremlin. And lastly, 
we establish a primary limb cell culture method that can be utilized in a medium throughput 
manner to manipulate gene expression and test the activity of DNA elements. This work 
provides the first characterization of the spatiotemporal response of a large group of GLI 
target genes. Furthermore, this work lays the foundation for a systems-level understanding 
of the gene regulatory networks underlying SHH-mediated limb patterning. 
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Chapter 1: Hedgehog, limb development, and transcriptional control 
 
 
1.1: FUNCTIONS OF HEDGEHOG SIGNALING  
The Hedgehog (HH) family of secreted proteins are critical regulators of embryonic 
development across a variety of metazoans. The responses elicited by the HH pathway vary 
greatly; HH signaling acts as an inductive signal for transcription, promotes cell 
proliferation, enables cell survival, and regulates tissue homeostasis (reviewed in Wilson 
and Chuang, 2010). In addition to the key roles in development, dysregulation of the HH 
pathway has been implicated in several types of cancer. 
In mammals there are three homologs of HH: desert hedgehog (Dhh), Indian 
hedgehog (Ihh), and sonic hedgehog (Shh), each of which have key functions in organizing 
tissue growth and patterning during embryonic development. Among the key roles, Dhh 
regulates germ cell formation in the testis, Ihh regulates both bone and cartilage 
development, and Shh regulates neural, muscle, and limb development (reviewed in Jiang 
and Hui, 2008). Because the HH pathway is employed iteratively during development, it 
is feasible to utilize several developing tissues as a model to study the pathway. 
 
1.1.1: Hedgehog signaling in limb development 
The developing vertebrate limb bud, readily amenable to genetic and embryological 
approaches, is a well-established model system used to study the HH signaling pathway. 
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In the vertebrate limb bud, Shh is expressed in the posterior margin (termed the zone of 
polarizing activity) (Chang et al., 1994; Riddle et al., 1993) (Fig. 1.1). This region was 
identified in a series of tissue transplant experiments in chicken looking for limb tissue 
with anterior-posterior organizing activity (Saunders and Gasseling, 1968). Since Shh 
encodes a secreted protein, SHH activity reaches over half of the limb as indicated by the 
pathway target gene Gli1 (Fig. 1.1). 
 
                       
Figure 1.1: Illustration of an E10.5 mouse embryo and forelimb. Shh mRNA expression 
domain is shown in green.  Gli1 mRNA expression domain (SHH activity area) is shown 
in graded black.   
 
In the developing vertebrate limb bud, Shh functions to regulate digit number and 
growth (Chiang et al., 1996; Towers et al., 2008; Zhu et al., 2008). This occurs through a 
signaling loop involving the regulation of a BMP inhibitor, gremlin 1 (Grem1) (Zuniga et 
al., 1999, Panman et al., 2006, Zuniga et al., 2012; Li et al., 2014; Vokes et al., 2008). 
GREM1 inhibits localized BMP activity, thereby maintaining the apical ectodermal ridge 
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(AER), which propagates a signaling loop between the mesoderm and the AER, thereby 
regulating limb growth and digit number (Khokha et al., 2003; Litingtung et al.,  2002; 
Michos et al., 2004; te Welscher et al., 2002; Zuniga et al., 1999) (Fig. 1.2). The importance 
of regulating Grem1 is discussed in Chapter 4.  
 
 
Figure 1.2: Schematic of SHH-GREM1-FGF signaling regulatory loop during limb 
development. Gene expression domains: green depicts sonic hedgehog (SHH), light orange 
depicts bone morphogenetic protein (BMP), dark blue depicts Gremlin 1 (GREM1), and 
light blue in the apical ectodermal ridge (AER) depicts FGF expression.   
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1.1.2: Hedgehog signaling in human disease 
Considering the critical functions of HH signaling during development, it is not 
unexpected that dysregulation of the pathway’s upstream or downstream components lead 
to a broad spectrum of human congenital birth defects and cancers.  Major defects in the 
pathway lead to severe neural abnormalities (holoprosencephaly, exencephaly, and 
cyclopia) and ultimately embryonic lethality (reviewed in Murdoch and Copp, 2010). Less 
severe defects in the pathway are associated with human abnormalities including: extra 
digits (polydactyly), shorter limbs, missing digits, and craniofacial defects (reviewed in 
Anderson et al., 2012) . In addition to the variety of developmental deformities, 
dysregulation of the HH pathway is also implicated in several types of cancer.  Mutations 
in the HH receptor, patched 1 (Ptch1), are found in human skin cancers (basal cell 
carcinomas) and aggressive brain tumors (medulloblastomas) (Kool et al., 2014, Pietsch et 
al., 1997; Fan et al., 1997; Gailani et al., 1996, Johnson et al., 1996). Taken together, 
defects in the HH pathway are critical drivers of various human pathologies. 
 The extensive connections between HH signaling and disease have generated much 
interest in determining how the HH pathway is regulated and its elicited cellular responses. 
The subsequent sections summarize of key aspects of HH signal transduction, temporal 
responses to HH ligand, and a compendium of the transcriptional control mechanisms used 
to regulate HH target genes.    
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1.2: HEDGEHOG SIGNAL TRANSDUCTION 
The HH signaling pathway regulates growth and patterning in multiple tissues 
during embryogenesis. Secreted HH ligands can spread over several cell diameters, 
eliciting both short and long-range effects (Chamberlain et al., 2008; Li et al., 2006; 
Nahmad and Stathopoulos, 2009; Sanders et at., 2013). In vertebrates, the HH signaling 
pathway is regulated by the primary cilia, a microtubule-based cellular protrusion 
(reviewed in Goetz and Anderson, 2010) (Fig. 1.3). HH-receiving cells ultimately respond 
by modulating the activity of the downstream GLI transcription factors (GLI1-3, homologs 
of Ci in Drosophila). In the absence of HH ligand, GLIs are partially degraded by the 
proteasome, forming a truncated protein that functions as a transcriptional repressor (GLI-
R). Conversely, in the presence of HH ligand, processing of GLI proteins to transcriptional 
repressors is inhibited, permitting the formation of full-length GLI activators (GLI-A) 
(Aza-blanc et al., 1997; Méthot and Basler, 1999; Pan et al., 2006; Wang et al., 2000) (Fig. 
1.3). Reducing the levels of GLI-R and favoring GLI-A elicits a diverse transcriptional 
response of GLI target genes (further discussed in Chapter 2).  
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Figure 1.3: Simplified illustration of the Hedgehog signaling pathway. Patched 1 
(PTCH1), suppressor-of-fused (SUFU), smoothened (SMO), cis-regulatory module 
(CRM), hedgehog (HH), Gli activator (GLI-A), Gli repressor (GLI-R). Cellular protrusion 
is the primary cilia.   
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1.3: TRANSCRIPTIONAL CONTROL OF GLI TARGET GENES 
The timing and duration of SHH is important for establishing polarity within the 
limb bud (Li et al., 2014; Zhulyn et al., 2014), and there is some evidence suggesting that 
cells retain a memory of their exposure to SHH (Harfe et al.,  2004). In addition, studies 
have indicated that a relatively brief exposure to SHH specifies digit patterning, while 
longer exposures are needed for subsequent growth and expansion of the autopod and digit 
progenitor cells (Towers et al., 2008; Zhu et al., 2008) (Fig. 1.4). The differential 
requirements of SHH for digit specification and growth suggest there are GLI target genes 
with distinct temporal requirements for SHH. While a few studies have determined the 
temporal requirement for HH signaling for a limited number of GLI target genes (further 
discussed in Chapter 2), a number of outstanding questions remain: What is the temporal 
requirement of HH signaling for a broad group of GLI target genes? What are the molecular 
mechanisms underlying the temporal transcriptional responses? 
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Figure 1.4: Model of digit specification and growth during limb development. (A) 
Schematized developing limb buds showing specification of early digit progenitors and 
subsequent expansion. (B) Schematized skeletal phenotypes when Shh is removed during 
the digit specification period and during the growth phrase. Gray ovals represent digit 
progenitors and growing digit rays, and dashed lines represent undergrown digits.  
 
1.3.1: GLI co-factors 
GLI proteins activate or repress target gene transcription by binding to a similar 
DNA sequence motif (TGGGTGGTC) within a cis-regulatory module (CRM) (Hallikas et 
al., 2006; Peterson et al., 2012). Transcriptional responses to the HH pathway can be 
 9 
elicited either by de-repression of GLI-R or in other cases, by transcriptional activation 
through GLI-A (further discussed in Chapter 4) (reviewed in Falkenstein and Vokes, 2014). 
In addition, recent studies suggest that additional tissue-specific factors are necessary for 
activating appropriate GLI target genes (Biehs et al., 2010). In the neural tube, GLI-bound 
CRMs are enriched for SOX binding motifs, and SOX2 and SOXB1 acts as a neural-
specific GLI co-factors (Oosterveen et al., 2012; Oosterveen et al., 2013; Peterson et al., 
2012). The mechanisms underlying transcriptional specificity in other Hh-mediated 
developmental processes remain unknown.   
 
1.3.2: GLI DNA motif quality  
A recent study in the mouse neural tube suggests that the quality (with respect to 
the consensus sequence) of Gli binding sites (GBS) in CRMs function in a temporal 
response for GLI target genes (Peterson et al., 2012). In addition, evidence from several 
studies indicate that GBS quality is an important factor in the spatial readout of Shh 
signaling. In the chick neural tube, GLI target genes closest to the HH signaling source are 
associated with CRMs that have higher quality Gli binding sites (GBS), while genes farther 
away are associated with CRMs that contain lower quality GBS (Oosterveen et al., 2012). 
Similarly, in the Drosophila imaginal wing disc, a CRM that controls the expression of a 
broadly expressed gene, Dpp, contains multiple low quality Ci sites, whereas a CRM that 
controls the expression of a gene, Ptc, which is closer to the Hh signaling source, contains 
high quality Ci sites (Parker et al., 2011). It is interesting to speculate that the quality of 
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the GBS may play a role in the temporal response of target genes in the developing mouse 
limb. 
 
1.4: CONCLUDING REMARKS 
The iterative use of the Hedgehog signaling pathway throughout embryonic 
development highlights the importance of the pathway. Moreover, implications of the 
Hedgehog pathway in cancers, make understanding the molecular mechanisms regulating 
this pathway critical to human health.  Over the past several decades much information has 
been discovered about the Hedgehog pathway; however, there are a numbers of outstanding 
questions pertaining to the transcriptional control mechanisms and tissue-specific 
responses. 
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Chapter 2: Spatiotemporal regulation of GLI target genes in the limb 
 
Contributing to this work: Lewandowski, J.P., Du, F., Zhang, S., Powel, M.B., Ji, H., 
and Vokes, S. A. Spatiotemporal regulation of. GLI target genes during mammalian limb 
development (manuscript in revision). J.P.L., F.D., S.Z., H.J., conceived experiments, 
and collected and interpreted data; M.B.P performed experiments.   
 
2.1: INTRODUCTION 
As mentioned in Chapter 1, GLI proteins convert Sonic hedgehog (Shh) signaling 
into a transcriptional output. The mechanisms by which GLI proteins activate and sustain 
gene expression in response to SHH are not well understood. The timing and exposure of 
SHH is clearly important; however, only a few studies have investigated the temporal 
requirement for SHH signaling on the level of individual genes (Bénazet et al., 2009; 
Drossopoulou et al., 2000; Panman et al., 2006; Scherz et al., 2007; Zuniga et al., 2004).  
To address this in the limb, we undertook a systems level analysis to determine the 
spatiotemporal kinetics of the GLI transcriptional response.  
In previous work, we used chromatin immunoprecipitation (ChIP) to identify GLI 
binding sites and intersected these with microarray gene expression datasets from Shh 
mutants in order to predict a set of approximately 200 putative direct GLI target genes in 
the developing limb bud (Vokes et al., 2008). Here, we extend these studies and determine 
the expression domains of our predicted GLI target genes in the mouse limb. Using this 
approach we found three distinct expression domains for GLI target genes. We then show 
that genes within these domains have different temporal SHH signaling requirements for 
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establishing their expression.  Further, we find that the GLI-bound CRMs associated with 
genes in each domain are enriched for both unique and common DNA motifs including 
one for SP-family transcription factors. Finally, we provide evidence that SP-mediated 
transcription is critical both for initiating and sustaining a subset of GLI target genes. We 
speculate that SP proteins may represent a way of transferring transcriptional control from 
transient inductive signals to ubiquitously expressed factors that maintain transcription. 
Collectively, these results provide the first characterization of the spatiotemporal response 
of a large group of GLI target genes, and lay the foundation for a systems-level 
understanding of the gene regulatory networks underlying SHH-mediated limb patterning.  
 
2.2: GLI TARGET GENES CLUSTER INTO THREE DOMAINS 
The expression patterns of 199 of 205 previously predicted GLI target genes (Vokes 
et al., 2008) were determined at E10.5 and E11.5 (Fig. 2.1A). Of the 199 genes analyzed, 
96% (n=191) were detected in embryos at E10.5, and of these, 90% (n=171) were detected 
in the limb (13 of 19 genes not detected in the limb by in situ at E10.5 were detected at 
E11.5). We classified genes on the basis of their expression pattern in the limb at E10.5 
(Fig. 2.1B, Table 2.1, Fig. A1, and Table A1) and subsequently focused on understanding 
genes predominately expressed in the SHH-responsive posterior limb (Fig. 2.2A and Table 
2.1).  
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Figure 2.1: in situ hybridization screen for GLI target genes (A) in situ hybridization 
pipeline for 199 GLI target genes. (B) Distribution of expression patterns in the limb.   
 
We searched for genes that were predominately expressed in the posterior limb bud, 
a region that is responsive to SHH signaling as defined by the expression of pathway target 
genes Gli1 and Ptch1 (Fig. 2.2A) (Litingtung et al., 2002; Marigo et al., 1996; te Welscher 
et al., 2002; Chiang et al., 2001; Ahn et al., 2004). Posteriorly expressed genes cluster into 
three broad domains (Fig. 2.2B-D, Table 2.1, Fig. A1, and Table A1). Category 1 contained 
24 genes expressed in the posterior and posterior-distal limb bud (Fig. 2.2B). Genes in this 
category included the SHH pathway target genes Gli1, Ptch1, and Ptch2 (Chiang et al., 
2001; Litingtung et al., 2002; te Welscher et al., 2002; Marigo et al., 1996; Motoyama et 
al., 1998). Category 2 comprised 12 genes expressed in the central limb (Fig. 2.2C), and 
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category 3 contained 9 genes that were expressed in the posterior-proximal limb (Fig. 
2.2D). Lastly, we identified 14 genes expressed in multiple domains, where at least one 
expression domain was spatially located within the SHH-responsive region. Because these 
may have more complex forms of regulation we excluded these genes from further analysis 
(Fig. A5). Altogether, we identified 45 genes that were expressed in three domains in the 
limb bud. 
The identification of distinct expression domains in the limb suggested that these 
domains might have specific biological functions. We explored this possibility by 
determining enriched biological processes for each category using GO ontology term 
analysis (WebGestalt) (Zhang et al., 2005). Category 1 was notably enriched for 
transcriptional regulation and cell proliferation processes (P≤0.000001) (Fig. 2.3). In 
contrast, category 2 was notably enriched for cell differentiation, cell adhesion, and 
ossification processes (P≤0.05), and category 3 was enriched for skeletal development 
processes (P≤0.05) (Fig 2.3). Differential enrichment within these categories suggests that 
the three distinct SHH-mediated domains in the limb may have unique functions.  
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Figure 2.2: GLI target genes cluster into three distinct domains within the SHH-
responsive region. (A) Schematic of E10.5 mouse limb showing Shh expression (green) 
and the SHH-responsive region (dark gray). (B-D) Schematized expression patterns 
observed for GLI target genes in individual categories depicted in red, light blue, and 
purple. Representative in situ images at E10.5 are shown. (B) Category 1 contains genes 
expressed in the posterior and posterior-distal limb (n=24), (C) Category 2 comprises genes 
expressed in the central limb (n=12), and (D) category 3 contains genes expressed in the 
posterior-proximal limb (n=9). White arrows indicate expression in the posterior-proximal 
domain. 
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Figure 2.3: GLI target genes expressed in different domains in the limb are enriched for 
unique GO biological processes. Genes in each category were compared with the mouse 
reference sequences using GO ontology terms (WebGestalt). The expected number of 
terms for the given sample size are in gray, and observed terms from the input genes are in 
blue. The comparison used a hypergeometric distribution to calculate the statistic for each 
category.  Terms in category 1 have a significance level of P=0.000001 with a minimum 
of 8 genes in each category. Terms in category 2 and 3 have a significance level of P=0.05 
with a minimum of 2 genes in each category. 
 
Our categorization of expression patterns was based on E10.5 limb buds. Because 
SHH signaling within the limb bud is dynamic, it is possible that the expression of GLI 
target genes within these domains could also be dynamic. To assess this, we examined the 
temporal changes in the expression domains of GLI target genes by comparing their 
expression patterns between E10.5 and E11.5. Most genes expressed in a particular domain 
at E10.5 remain expressed in a broader version of the same domain at E11.5 (category 1, 
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n=18/24; category 2, n=9/12; category 3, n=8/9) (Fig. 2.4 and Figs. A2-4). Taken together, 
these results indicate that the expression domains of GLI target genes are relatively stable 
despite the large changes in SHH signaling that occur during this period. In summary, we 
identified three stable domains of GLI target gene expression within the SHH-responsive 
region of the limb bud.  
 
 
Figure 2.4: GLI target genes maintain early expression domain. (A-C)  Schematized 
expression domains in E10.5 and E11.5 limbs for GLI target genes. Expression domains at 
E11.5 are broader (indicated in gray). Number of genes in each category expressed in the 
same domain at E10.5 and E11.5: (A) category 1, n=18/24),  (B) category 2 (n=9/12), and 
(C) category 3 (n=8/9). 
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2.3: GLI TARGET GENES HAVE DIFFERENT TEMPORAL REQUIREMENTS FOR SHH 
GLI target genes require SHH signaling for transcriptional activation or robust 
expression; however, subsequent requirements for SHH signaling have been determined 
for only a few GLI target genes. For example, Hoxd13 requires SHH signaling for 
activation and continues to require SHH to maintain expression beyond E10.75 (Panman 
et al., 2006). In contrast, Jag1, requires exposure to SHH signaling through E10.25 before 
expression becomes independent of SHH signaling (Panman et al., 2006). We sought to 
determine the temporal requirement of SHH signaling for the group of 45 GLI target genes 
expressed in the posterior limb. To determine whether transient SHH activation was 
required for expression of GLI target genes, we cultured E10.25 wild-type limbs, which 
have already expressed Shh, in the presence of a HH pathway inhibitor, cyclopamine (Chen 
et al., 2002). If gene expression was maintained after transient SHH exposure, but 
downregulated in Shh-/-, then SHH is required only transiently for GLI target gene 
expression. In contrast, if genes required continued exposure to SHH, they would remain 
downregulated in wild-type limb buds that received a brief exposure to SHH. While 
previous studies have identified SHH-responsive genes at E10.5 using microarrays (Probst 
et al., 2011; Shah et al., 2009), we decided to perform a new analysis using RNA-seq on 
E10.25 limb buds in order to make direct quantitative comparisons (Fig. 2.5).  
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Figure 2.5: Schematic depicting RNA-seq pipeline. (A) Shh expression indicated in 
green. Forelimb samples with different SHH exposures indicated as WT, No SHH, and 
Brief SHH. 
 
Using littermate E10.25 (32-35 somites) wild-type and Shh-/- forelimbs, we 
identified 297 SHH-responsive genes downregulated ≥25%, (Log2FC≤-0.4105) with a 
false discovery rate (FDR) ≤0.05 (Table B2). Among these downregulated genes, we 
identified several known GLI target genes: Gli1, Ptch1, Hhip, HoxD13, Grem1, and Hand2 
(Table 2.1 and Table B2) (Bénazet et al., 2009; Chiang et al., 2001; Litingtung et al., 2002; 
Panman et al., 2006; Vokes et al., 2008; te Welscher et al., 2002). To determine which of 
these genes continue to require SHH, we cultured E10.25 (31-34 somites) wild-type 
forelimbs for 15 hours in either control media or media containing cyclopamine, a Hh 
pathway inhibitor which antagonizes Smoothened (Smo) (Chen et al., 2002; Panman et al., 
2006). Within this dataset, we identified 61 genes downregulated ≥25% (Log2FC≤-0.4105) 
with a FDR≤0.05. Consistent with previous reports, several genes that continue to require 
SHH at E10.25 were confirmed in our dataset: Gli1, Hoxd11, Hoxd12, and Hoxd13 (Table 
2.1 and Table B1) (Panman et al., 2006).  
Next, we asked if the 45 GLI target genes predominately expressed in the posterior 
limb have differential requirements for SHH signaling. To determine genes that require 
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sustained SHH signaling, we identified genes that were downregulated ≥25% (Log2FC≤-
0.4105) with a FDR≤0.1 in both datasets (Fig. 2.6A). One gene, Runx3, was excluded from 
the analysis because of a low read count in one dataset. Among the group, 18 out of 44 
genes were statistically downregulated in both Shh-/- limbs and limbs treated with 
cyclopamine (Fig. 2.6B and Table 1, indicated with an asterisk). Interestingly, nearly all of 
the genes found downregulated in both datasets (n=15) were expressed in category 1 
(posterior and posterior-distal), making it significantly enriched for genes requiring 
sustained SHH (two-sided Fisher’s exact test, P=0.0018) (Table 2.1, indicated with an 
asterisk). 
To determine the genes that require a transient exposure to SHH signaling, we 
identified genes downregulated ≥25% (Log2FC≤-0.4105) with a FDR≤0.1 in Shh-/- limbs 
that had unchanged expression relative to wild-type limbs cultured in cyclopamine. Among 
the group of 44 genes, 5 genes were statistically downregulated in Shh-/- limbs but 
unchanged relative to controls in cyclopamine treated limb cultures (Fig. 2.6C and Table 
2.1, indicated with a double dagger). All of these genes were expressed in categories 2 and 
3, suggesting that in contrast to category 1, categories 2 and 3 have more transient 
requirements for SHH.   
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Figure 2.6: GLI target genes have distinct temporal requirements for SHH. (A) Heatmap 
showing expression for GLI target genes in categories 1-3 across eight RNA-seq samples: 
WT, wild-type; Shh-/-; Ctrl, control; Cyc, cyclopamine. (B-D) Scatter plots showing 
expression (Log2FC) of GLI target genes in Shh-/- (No SHH) and cyclopamine (Brief SHH) 
samples.  Blue lines at 0 indicate no change in expression, and red lines indicate the 
downregulated cutoff (Log2FC = -0.4105). (B) Statistically downregulated GLI target 
genes in both Shh-/- and cyclopamine samples (n=18). (C) GLI target genes statistically 
downregulated in Shh-/-, but unregulated in cyclopamine sample (n=5). (D) GLI target 
genes unable to make a statistical determination (n=21). Expression values for genes in C-
E indicated in Table 2.1.  
 
The expression values for 21 out of the 44 genes were not different enough to make 
a statistical determination; they were neither significantly reduced nor statistically 
unchanged (Fig. 2.6D and Table 2.1). These genes, downregulated in Shh-/- limb buds, 
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could represent a category that is in the process of becoming transcriptionally independent 
of SHH signaling. In summary, we found that genes expressed in the posterior and 
posterior-distal (category 1) tend to require a longer exposure to SHH signaling in order to 
maintain expression, while genes expressed in the central (category 2) and posterior-
proximal (category 3) tend to require a shorter exposure to SHH before expression becomes 
independent. We conclude that GLI target genes have differential requirements for SHH 
signaling, and that the transcriptional regulation of GLI target genes correlates with where 
they are expressed. 
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Table 2.1: Classification and expression of GLI target genes. Schematized expression 
patterns of GLI target genes found in categories 1-3. List of GLI target genes found in each 
category.  Gene expression values in log2 fold change (FC) from RNA-seq experiments 
(shown in Fig. 3). Hedgehog pathway targets are underlined. Genes downregulated ≥25% 
(Log2FC≤-0.4105) in both Shh-/- limbs and cyclopamine treated limbs are indicated with 
an asterisk (*) and shown in red. Genes downregulated ≥25% (Log2FC≤-0.4105) in Shh-/- 
limbs but unregulated (Log2FC≥0) in the cyclopamine experiment are indicated with a 
double dagger (‡). 
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2.4: DNA MOTIF ANALYSIS IN CIS-REGULATORY MODULES 
The 45 genes defined above are highly likely to be directly regulated by SHH 
signaling through their associated GLI-bound CRMs. To identify co-factors potentially 
involved in mediating the GLI response, we searched the GLI-bound CRMs associated 
with these genes for enriched DNA motifs using de novo motif analysis (Ji et al., 2008; Ji 
et al., 2006). We uncovered novel DNA motifs enriched in categories 1 and 2. No enriched 
motifs were uncovered for CRMs associated with genes in category 3 due to the small 
sample size (Fig. 2.7A,B). The most enriched motif in any category was Gli, which was 
substantially enriched in GLI-bound CRMs associated with category 1 genes compared to 
matched genomic controls (Fig. 2.7A). We also identified a GC rich motif which 
corresponded to the known binding motif for the SP1 transcription factor (Fig.2.7A) 
(Gidoni et al., 1984; Ji et al., 2006). In addition to being enriched in category 1, the Sp1 
motif was the most enriched motif found in category 2 (Fig. 2.7B). We also identified 
several novel motifs that are highly sequence specific; however, they do not correspond to 
any known transcription factor binding sites (Fig. 2.7A,B). Thus, DNA motif analysis 
identified both unique and common motifs among two of the expression categories. 
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Figure 2.7: DNA motifs enriched in GLI-bound CRMs. (A) Enriched DNA motifs in 
GLI-bound CRMs associated with category 1 and (B) category 2 genes. Known and 
unknown protein binding motifs and the enrichment value are indicated. No statistically 
enriched DNA motifs were identified in category 3.  
 
The quality of Gli motifs have been shown to function in differential interpretation 
of HH signaling in the developing mouse neural tube and Drosophila imaginal wing disc 
(Oosterveen et al., 2012; Parker et al., 2011; Peterson et al., 2012). We asked if the different 
expression categories had differences in Gli motif quality. We chose the Gli motif with the 
highest motif score in our dataset and mapped the position weight matrix of the Gli motif 
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to GLI-bound CRMs associated with genes expressed in categories 1, 2, and 3. Gli motifs 
associated with genes expressed in category 1 and 3 have higher means of log-likelihood, 
indicating higher quality Gli motifs (Fig. 2.8). In contrast, Gli motifs associated with 
category 2 have a lower (although not statistically significant) mean of log-likelihood, 
indicating lower quality Gli motifs (Fig. 2.8). Interestingly, genes in categories 1 and 3 are 
expressed overlapping or are adjacent to the Shh expression domain in the posterior limb, 
while genes in category 2 are expressed further from the Shh expression domain. This 
suggests that long-range SHH signaling could regulate category 2 genes. The same trends 
in Gli motif quality were also observed in the mouse neural tube and Drosophila imaginal 
wing disc for short and long range GLI target genes (Oosterveen et al., 2012; Parker et al., 
2011).  
                                                  
Figure 2.8: Assessment of the quality of Gli motifs in GLI-bound CRMs. CRMs 
associated with genes found in categories 1-3 shown as log2 likelihood ratio. Reported p-
values using a Welch’s t-test for comparing Gli motif quality between the categories: 
Category 1 to 2 (P=0.083); category 1 to 3 (P=0.776); category 2 to 3 (P=0.144). 
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2.5: SP-MEDIATED TRANSCRIPTION 
As an initial step towards determining the functional importance of these motifs, 
we decided to focus on the Sp1 motif, which was identified in both categories 1 and 2. In 
the limb mesenchyme Sp1, Sp2, and Sp3 are expressed in a mostly uniform pattern at E10.5 
(Saffer et al., 1991; Yokoyama et al., 2009; Baur et al., 2010). Both SP1 and SP3 bind to 
the same DNA motif with similar affinities, suggesting that both could be binding this 
motif in the limb (Hagen, Muller, Beato, Suske, & Marburg, 1992). While roles for SP-
family proteins in the early limb bud mesenchyme have not been studied, several Sp 
members have been characterized within the ectoderm, including Sp6, which has been 
proposed to regulate Wnt expression in the AER (Talamillo et al., 2010), and Sp8 and Sp9, 
which regulate Fgf8 expression in the AER and likely bind a similar DNA motif sequence 
as SP1 (Bell et al., 2003; Kawakami et al., 2004; Sahara, Kawakami, Izpisua Belmonte, & 
O’Leary, 2007; Treichel, Schöck, Jäckle, Gruss, & Mansouri, 2003).  
Consistent with previous reports, Sp1 is expressed throughout much of the embryo, 
including the forelimbs (Fig. 2.9A). Although the Sp1 locus has a closely associated GLI-
bound CRMs and was initially predicted to be a GLI target gene (Vokes et al., 2008), Sp1 
gene expression is not affected in Shh-/- forelimbs (Fig. 2.9B). In addition, SP1 does not co-
immunoprecipitate with GLI1 in the mouse limb (Fig. 2.9C). 
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Figure 2.9: Sp1 is expressed in the forelimb and is not regulated by SHH. (A) in situ 
hybridization for Sp1 in wild-type (WT) E10.5 embryo and forelimb. (B) qRT-PCR for 
Sp1 in 33-35 somite WT (open bar) and Shh-/- (gray bar) forelimbs. Error bars indicate the 
standard error of the mean (n=3). (C) Western blot of GLI1FLAG co-immunoprecipitation 
(co-IP) for SP1 in E10.5 mouse forelimbs from PrxCre; RosaGli1-Flag embryos. SP1 is 
detected in the input sample, but is not detected in the co-IP sample. As a control, GLI1FLAG 
is detected in the co-IP sample. 
 
To determine if SP-mediated transcription contributed to the regulation of GLI target 
genes, we cultured contralateral mouse forelimbs in media with or without 300nM 
mithramycin A (Fig. 2.10), an antibiotic that has been shown to bind to GC rich DNA 
sequences and selectively inhibit SP-mediated transcription (Blume et al., 1991; García-
Huerta et al., 2012; Guo, Rödelsperger, Digweed, & Robinson, 2013; Snyder, Ray, Blume, 
& Miller, 1991; Van Dyke & Dervan, 1983). To assess the level of inhibition for SP-
mediated transcription, we determined the expression levels of Fgf8 and found it was 
strongly downregulated, which is consistent with its regulation by Sp8 and Sp9 (Fig. 
2.10B,C). Next, we assessed the expression levels for a selected group of GLI target genes 
from categories 1, 2 and 3. Limb buds cultured in media containing mithramycin A have 
reduced expression levels of selected GLI target genes across all expression categories 
(Fig. 2.10C). Consistent with the reductions observed by qRT-PCR, limb buds cultured in 
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the presence of mithramycin A also have reduced levels of gene expression when assayed 
by in situ hybridization (Fig. 2.10D).  
 
 
Figure 2.10: SP-mediated transcription is required to maintain expression of GLI target 
genes. (A) Schematic of contralateral mouse forelimb culture. (B-D) Wild-type (WT) 
E10.25 (32-35 somites) forelimbs cultured in control media with the contralateral limbs 
cultured in 300 nM mithramycin A for 15 hours, and were assayed by in situ hybridization 
or qRT-PCR (B) in situ hybridization for Fgf8 (C) qRT-PCR for expression of selected 
GLI target genes. Gene expression is normalized to Gapdh in the control sample, dashed 
line at 100% indicates control gene expression, and error bars indicate the s.e.m (pools of 
9 contralateral forelimbs per condition, n=2). An asterisk indicates a statistically significant 
difference (two-tailed unpaired t-test, P≤0.05). (D) in situ hybridization of select GLI target 
genes.  
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FGFs in the AER are essential for maintaining Shh expression (Laufer, Nelson, 
Craig, Johnson, Morgan, & Tabin, 1994; Niswander, Jeffrey, Martin, & Tickle, 1994). 
Since Ptch1 and Gli1 are reduced by approximately 50%, this downregulation could be 
due to sensitivity to SHH pathway inhibition and/or by inhibition of mesodermal SP protein 
activity. To distinguish between these, we first examined the 5 GLI target genes that did 
not require continued SHH signaling (Table 2.1, indicated with a double dagger). From 
this group, 4 out of 5 genes were downregulated, 3 of them significantly (P≤0.05) in 
mithramycin A treated limb bud cultures. To ensure that reduction of these 4 genes (and 
the broader group) was not due to reduced FGF expression in the AER, we cultured limb 
buds in the presence of an FGF receptor antagonist, SU5402 (Mohammadi et al., 1997) 
(Fig. 2.11A). As expected, the FGF target genes sprouty 4 (Spry4) and dual specificity 
phosphatase 6 (Dusp6) were significantly reduced at 4, 8, and 15 hours (Fig. 2.11B-D) 
(Minowada et al., 1999).  While Shh expression was also reduced at 4, 8, and 15 hours, the 
pathway target genes Gli1 and Ptch1 were not significantly reduced, although showed 
variable expression (Fig. 2.11B-D). The majority of GLI target genes were not greatly 
reduced, and several genes that were strongly downregulated by mithramycin A were 
generally unaffected or even upregulated when cultured in SU5402 (Fig. 2.11E). This 
suggests that mithramycin A mediated reduction in GLI target gene expression is not solely 
due to the abrogation of the SHH-FGF signaling loop.   
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Figure 2.11: FGF inhibition does not downregulate most GLI target genes. Wild-type (32-
35 somites) forelimb cultured in 0.1% DMSO and the contralateral limb cultured in media 
containing 10 μM SU5042 (FGF inhibitor) for 4, 8, or 15 hours.  (B-D) Kinetics of FGF 
inhibition.  qRT-PCR for FGF and SHH pathway targets. (E) q-RT-PCR for GLI target 
genes at 15 hours. n=5 individual forelimb pairs. An asterisk indicates a statistically 
significant difference (two-tailed unpaired t-test, P≤0.05). The mean value is plotted at the 
top of the bar and error bars are the standard error of the mean. 
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To assess the specificity of mithramycin A and circumvent secondary effects 
caused by reduced SHH and FGF activity, we utilized a modified-micromass culture 
method for Shh-responsive genes that allows efficient knock-down of genes by siRNA 
while preventing differentiation of limb bud cells (Lewandowski, Pursell, Rabinowitz, & 
Vokes, 2014) (Fig. 2.12A). Limb cells electroporated with a Sp1 siRNA showed a 69% 
reduction in Sp1 expression at 48 hours compared to cells electroporated with a negative 
control siRNA (Fig. 2.12B). The expression of four independent GLI target genes were 
reduced >25% (Fig. 2.12C). This suggests that SP1, in the limb bud mesenchyme, 
contributes to maintain expression of GLI-target genes.  
 
 
Figure 2.12: Sp1 siRNA in micromass limb culture and qRT-PCR for GLI target genes.  
(A) Experimental pipeline. (B) qRT-PCR for Sp1 and Tbp (negative control gene) in 
control (black) and Sp1 siRNA (red) cultures. (C) qRT-PCR for GLI target genes. 
Statistical significance determined using an unpaired two-tailed T-test. Asterisk (*) 
indicates Pvalue <0.05. 
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We then asked if SP-mediated transcription is also required for SHH-dependent 
transcriptional activation of GLI target genes.  Although Shh-/- forelimbs have reduced or 
absent expression of GLI target genes, they are capable of activating expression in response 
to exogenous SHH protein (Panman et al., 2006). We cultured forelimbs from E10.25 (32-
34 somite) Shh-/- embryos and heterozygous or wild-type littermates in the presence of the 
HH pathway activator (purmorphamine) (Sinha et al., 2006), mithramycin A, or both small 
molecules (Fig. 2.13A). As expected, the GLI-target genes Ptch1, Msi2, Cdk6 and Osr2 
were reduced in Shh-/- forelimbs while a control gene, Tbp, was unchanged (Fig. 2.13B, 
white bars). Conversely, Shh-/- forelimbs cultured in the presence of purmorphamine had 
upregulated expression of Ptch1, Msi2, Cdk6, and Osr2 (Fig. 2.13B, blue bars). When Shh-
/- forelimbs were cultured in mithramycin A alone or together with purmorphamine, gene 
expression remained at levels comparable to control cultured Shh-/- forelimbs (Fig. 2.13B, 
red and yellow bars). These results suggest that activation of GLI target genes requires SP-
mediated transcription. In summary, SP proteins act as GLI transcriptional co-regulators 
that are required for both the transcriptional activation as well as for maintenance of GLI 
target genes.  
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Figure 2.13: SP-mediated transcription is necessary for transcriptional activation of GLI 
target genes (A) Schematic of contralateral mouse forelimb culture. Littermate wild-type 
or heterozygous (indicated as WT) and Shh-/- contralateral forelimbs (31-33 somites) 
cultured for 15 hours in control media (open bars), 300 nM mithramycin A (Sp inhibitor) 
(red bars), 10 μM purmorphamine (Hh activator) (blue bars), or both (yellow bars). (B) 
qRT-PCR for select GLI target genes: Ptch1, Cdk6, Msi2, and Osr2 as well as a control 
gene, Tbp.  Gene expression is normalized to Gapdh and error bars indicate a 95% 
confidence interval (per genotype, 3 contralateral limb buds for each condition). 
 
2.6: DISCUSSION  
In this study, we have identified a set of genes that by multiple criteria are direct 
GLI targets in the developing limb bud. These genes are expressed in three domains, which 
have distinct temporal requirements for SHH signaling in order to maintain expression. 
The GLI binding regions associated with genes in two of the domains are also enriched for 
additional motifs, representing binding sites for potential transcriptional co-regulators. One 
of these motifs corresponds to the binding sequence for SP1, which we show is important 
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for co-regulating a broad subset of GLI target genes in the limb bud. The identification of 
distinct transcriptional domains has greatly improved the understanding of HH patterning 
in the Drosophila imaginal wing disc and vertebrate neural tube. The presence of analogous 
domains within the limb bud (this study) should enable the determination of the gene 
regulatory networks underlying SHH-mediated limb patterning. 
 
2.6.1: Expression patterns of GLI target genes 
Whole-genome approaches, using DNA microarrays, have been used to identify 
SHH-responsive genes during limb development (Bangs et al., 2010; Hu, McGlinn, Harfe, 
Kardon, & Tabin, 2012; McGlinn et al., 2005; Probst et al., 2011; Shah et al., 2009; Vokes 
et al., 2008). Combining this approach with three-dimensional spatial information from 
whole-mount embryo in situ hybridization, has been successfully used to identify genes 
regulated in distinct domains (Bangs et al., 2010; Probst et al., 2011; Welten et al., 2011).  
Here, we focused on genes that were previously identified as likely GLI target genes and 
performed a comprehensive in situ hybridization screen to determine the limb expression 
patterns for nearly all of the 205 GLI target genes at two developmental stages. The 
previous studies were unable to distinguish direct and indirect effects in Shh-/- limb buds. 
By examining GLI targets, this study improves our understanding of the genes and 
processes directly controlled by SHH.  
 While our analysis identified a group of high confidence SHH regulated genes, a 
number of additional candidate GLI target genes did not show spatially restricted 
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expression in the posterior limb. Some of the genes that have uniform expression patterns 
are still likely to be SHH-responsive. For example, Rab34 has relatively uniform limb 
expression but is nonetheless SHH-responsive, containing a GLI binding site with 
posterior-specific activity (Vokes et al., 2007). Similarly, we detected many GLI target 
genes expressed in the distal limb and excluded them from further analysis because they 
were not primarily expressed within the SHH-responsive region (Fig. 2.1B and Table A1). 
A previous study classifying SHH-responsive genes suggested that Cyp26b1, a distally 
expressed gene and reduced in Shh-/- limbs, is primarily regulated by FGFs because of a 
breakdown in the SHH-FGF signaling loop (Probst et al., 2011). Since many of these 
distally expressed genes are in proximity to GLI binding regions, it is possible that they are 
co-regulated by SHH and FGF in a feed-forward loop. By restricting our analysis to 
spatially restricted genes in the posterior limb, we are therefore likely excluding many 
bona-fide GLI target genes that have more complex regulatory inputs.  
We identified three broad expression domains of GLI target genes (Fig. 2.2B-D). 
The coordinated expression of developmentally expressed genes, termed syn-expression 
groups, has been proposed to be involved in regulating common biological pathways 
(Gawantka, Pollet, Delius, Vingron, & Pfister, 1998; Ramialison et al., 2012; Visel et al., 
2007). Category 1 genes, expressed in the posterior and posterior-distal limb, are enriched 
for GO processes involved in transcriptional regulation and cell proliferation (Fig. 2.3). 
Consistent with these processes, the posterior-distal domain undergoes significant 
proliferative expansion during limb bud development, ultimately giving rise to most of the 
developing digits (reviewed in Zeller et al., 2009). If SHH acts as a morphogen in the limb 
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bud, it would likely be doing so through these category 1 genes. Interestingly, besides SHH 
pathway feedback components, we did not identify GLI target genes that had obvious 
graded expression in the limb. In contrast to category 1, GLI target genes expressed in 
category 2 (the central limb) are enriched for skeletal differentiation markers and BMP 
inhibitors (Fig. 2.3) (Hsu et al., 1998; Khokha et al., 2003; Rainger et al., 2011). Cells in 
this domain primarily contribute to the forearm (zeugopod) (Vargesson et al., 1997). 
Similarly, genes expressed in category 3 are enriched for skeletal pathway genes (Fig. 2.3). 
In addition, lineage tracing experiments demonstrate that this region primarily contributes 
to the presumptive forearm (Vargesson et al., 1997). 
 
2.6.2: Different temporal requirements for SHH 
Previous reports identified four GLI target genes within the limb bud that require 
sustained SHH signaling beyond E10.5 (Panman et al., 2006). Our analysis of the temporal 
requirement of SHH signaling for GLI target genes extends these results and provides 
quantitative measurements of the response, identifying a total of 18 GLI target genes that 
require sustained SHH signaling beyond E10.25 (Table 2.1, indicated in red and an 
asterisk). These genes are nearly all expressed in category 1, which might comprise a gene 
regulatory module that is important for mediating limb growth during the period when 
SHH signaling is required for expansion of the cartilage progenitors (Towers et al., 2008; 
Zhu et al., 2008). It is not clear why genes in categories 2 and 3 generally require a briefer 
exposure to SHH. One possibility is that since genes in categories 2 and 3 are expressed in 
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more proximal regions, their transient need for SHH signaling reflects the earlier 
differentiation of more proximal limb elements compared to distal elements (Roselló-Díez 
et., 2014). It is also possible that the lower Gli motif quality observed in GLI-bound CRMs 
associated with genes in category 2, reflects a requirement for regulating long-range target 
genes as has been suggested in the neural tube (Oosterveen et al., 2012). 
Although the RNA-seq analysis was specifically applied to a group of previously 
defined GLI target genes, the analysis also identified a larger SHH-responsive group of 
genes that require transient or continued SHH signaling. In future studies it would be 
interesting to identify the expression pattern of this larger group of SHH-responsive genes 
and determine to what extent they conform to the expression categories as described in this 
work. Based on our finding that the regulation of GLI target genes correlates with where 
they are expressed, we predict that genes requiring sustained SHH signaling will be 
predominately expressed in the posterior and posterior-distal limb (category 1), while 
genes that require transient SHH signaling will be expressed in the central (category 2) or 
posterior-proximal limb (category 3). 
 
2.6.3: Regulatory inputs in GLI-bound CRMs 
 
In current ChIP approaches, it is difficult to distinguish between transcriptionally 
relevant binding sites from the majority of inert sites in a particular tissue (Shlyueva et al., 
2014). We previously estimated that only 15% of GLI-bound CRMs are likely be 
transcriptionally relevant (Vokes et al., 2008). The GLI-bound CRMs associated with 
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genes in the domains identified in this study are a significant improvement on our previous 
approach, which only considered gene response irrespective of their spatial expression 
domains. 
From this set of GLI-bound CRMs we identified both unique and common DNA 
motifs. The unique motifs do not correspond to known transcription factor binding sites 
and might represent binding sites for unidentified co-factors that confer specific 
expression. After the Gli motif, the Sp1 motif was the most common motif identified in 
categories 1 and 2 (Fig. 2.7A,B). While Sp1 is a ubiquitously expressed gene, its expression 
levels are dynamic in different tissues and cell types (supplementary material Fig. S4A,B) 
(Saffer et al., 1991). Despite their reputation as ubiquitous transcription factors, several 
individual Sp-family genes have specific loss-of-function phenotypes, suggesting that they 
have specific roles in development (reviewed in Zhao and Meng, 2005; Suske et al., 2005). 
For example, Sp1 has been shown to regulate several developmental pathways including 
neuronal differentiation (Okamoto, Sherman, Bai, & Lipton, 2002; Yoo et al., 2002), 
hematopoiesis (Gilmour et al., 2014), and most relevant to limb, cartilage and bone 
differentiation (Kasaai et al., 2013; Gene et al., 2006; Zhang et al., 2009). Moreover, 
previous studies have demonstrated that SP1 can mediate the interaction of distal 
regulatory elements with the proximal promoter region of a gene (Deshane et al., 2010; Su, 
Jackson, Tjian, & Echols, 1991).  
The Sp1 motif was also enriched in a GLI1 ChIP-seq dataset on ventral neural tissue 
(Peterson et al., 2012) as well as in several other published limb ChIP datasets, indicating 
that its enrichment is not specific to GLI  CRMs. Our work suggests that SP1 is an 
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important co-regulator for GLI target genes in the limb. In future studies, it will be 
interesting to explore these interactions in more detail. In the absence of this information, 
we present a speculative model for these interactions (Fig. 2.14). Here, SP1 is depicted as 
an essential co-factor for activating GLI target genes as well as controlling their later 
maintenance after genes no longer require SHH. As GLI1 and SP1 do not bind to each 
other (Fig. 2.9C), it is possible that SHH signaling would activate GLI-dependent CRMs 
and upon activation, SP1 would facilitate interactions between the CRM and the promoter 
(Fig. 2.14).  
 
 
Figure 2.14: Speculative model illustrating the roles of GLI and SP1 in activating and 
maintaining GLI target gene expression.  Prior to SHH, GLI dependent CRMs are inactive 
(depicted as gray in left panel). After the expression of SHH, GLI-R is inhibited, resulting 
in the activation of target gene expression by through physical interactions between the 
CRM and basal promoter that are facilitated by SP1. The length of the activation stage is 
variable, depending on the specific gene / domain. Ultimately, GLI target genes no longer 
require SHH signaling but many still require SP transcription, perhaps to maintain CRM-
promoter interactions. 
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Interestingly, in Drosophila, Sp1 is broadly expressed in the imaginal disc and is 
required for leg development (Estella and Mann, 2010; McKay et al., 2009; Estella et al., 
2003). In this system, Sp1 is involved in feed-forward loops that regulate specific enhancers 
that turn on genes involved in leg growth (Estella and Mann, 2010). Previous work has 
noted the presence of Dlx, Hox and Meis in both Drosophila and vertebrate limb 
development. Although Drosophila and vertebrate limbs evolved independently, the 
presence of these deeply homologous genes in both systems suggests they may be required 
for sub-circuits required for appendage formation (Shubin et al., 2009). Sp1 may therefore 
represent an additional deeply homologous gene required for appendage development in 
vertebrates. 
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Chapter 3: A GLI silencer robustly represses gremlin in the limb bud 
 
Portions of this chapter are modified with permission from the authors. Li, Q*., 
Lewandowski, J. P*., Powell, M. B., Norrie, J. L., Cho, S. H., & Vokes, S. A. A Gli 
silencer is required for robust repression of gremlin in the vertebrate limb bud. 
Development (2014) 141(9)1906-19014. Q.L., J.P.L. and J.L.N conceived experiments, 
collected and interpreted data. M.B.P and S.H.C performed experiments.   
 
3.1: INTRODUCTION 
Gli transcriptional targets fall into two distinct groups: genes that require Gli 
activation for transcription (Gli activator genes), and genes that are transcribed in the 
absence of Gli repression (Gli derepression genes). Gli activators could potentially play 
quantitative roles in regulating the expression levels of a subset of this latter class. The 
behavior of target genes in response to a gradient of Hh signaling suggests that competition 
between Gli activators and repressors could drive threshold responses that restrict the 
boundary of Gli-activator target gene expression (Jacob and Briscoe, 2003; Ruiz i Altaba, 
1997; Wang et al., 2000). Studies that have manipulated Gli expression levels in the chick 
neural tube support this competition model (Oosterveen et al., 2012).  The mechanism by 
which Gli repression prevents expression of its target genes is poorly understood, but in 
some cases relies on interactions between Gli repressors and specific transcription factors 
(Oosterveen et al., 2012). Mouse neural tubes lacking the major Gli transcriptional 
repressor Gli3 have a relatively modest change in target gene expression boundaries with 
no change in ventral neural fates and more subtle changes to intermediate identities, an 
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effect that could be due to the robustness of the neural-specific downstream regulatory 
network (Balaskas et al., 2012; Persson et al., 2002).  
Sonic hedgehog (Shh), the Hh ligand expressed in the limb bud, has graded activity 
emanating from the most posterior region of the limb bud. The dose and duration of Shh 
signaling are critical for specifying digits and regulating growth (Ahn and Joyner, 2004; 
Harfe et al., 2004; Towers et al., 2008; Yang et al., 1997; Zhu et al., 2008). When compared 
to Shh-/- embryos, Shh-/-;Gli3-/- embryos have a substantial rescue in limb growth and digit 
formation. The expression of many genes that are lost in Shh-/- limb buds are restored in 
Shh-/-;Gli3-/- embryos but with symmetrical gene expression patterns along the anterior-
posterior axis. This contrasts with their asymmetric expression in wild-type embryos and 
is exemplified by Gremlin, an important Shh target gene that encodes a protein playing key 
roles in regulating differentiation (reviewed in Rabinowitz and Vokes, 2012). Expression 
of Gremlin in the limb expands anteriorly in Gli3-/- embryos, is severely downregulated in 
Shh-/- embryos, and is rescued in Shh-/-;Gli3-/- embryos (Aoto et al., 2002; Litingtung et al., 
2002; Panman et al., 2006; te Welscher et al., 2002; Zuniga et al., 1999). Collectively, these 
studies illustrate the profound importance of Shh in counteracting Gli3-mediated 
repression of target genes.  
Despite the central role of Gli proteins in regulating Hh signaling responses, the 
mechanism by which Gli activator and repressor proteins collaboratively regulate target 
genes remains poorly understood and is an impediment to defining target genes and gene 
regulatory networks. We used a Gli cis-regulatory module (CRM) that is embedded within 
a global control region for the Gremlin locus to perform the first genetic characterization 
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(loss-of-function) of a Gli-responsive CRM. We find that the GRE1 (Gli responsive 
element 1) acts as both an enhancer and a silencer. GRE1 enhancer activity requires 
sustained Hh signaling to drive activity. In the anterior limb bud, GRE1 acts as a Gli-
dependent silencer.  The silencer activity is necessary for providing robust repression of 
Gremlin in the distal-anterior limb.  
 
3.2: GRE1 GENOMIC LANDSCAPE AND ACTIVITY DOMAIN 
In a genome-wide chromatin immunoprecipitation study, we previously identified 
a 438-bp Gli3 binding region located over 100kb downstream of Gremlin (Fig. 3.1A) that 
exhibited enhancer activity in transient transgenic limb buds in a region partially 
overlapping with Gremlin gene expression  (Fig. 3.1B-F) (Vokes et al., 2008). Enhancer 
activity is dependent on the presence of at least one Gli motif as mutations of the motif 
resulted in a complete lack of enhancer activity in G0 transgenic embryos (Vokes et al., 
2008). We sought to characterize Gli enhancer regulation in the context of this CRM, which 
is henceforth referred to as GRE1 (Gli responsive element 1). Embryos derived from three 
founder lines of stable transgenics had β-galactosidase activity in posterior limb bud 
mesenchyme in an identical domain to that previously reported for transient transgenics 
(Fig. 3.1B-F) (Vokes et al., 2008).  
We selected one line, Tg(Rr26-lacZ)438Svok, henceforth referred to as GRE1LacZ, 
for further analysis. β-galactosidase activity was first detected in embryos at E10.0 (31-32 
somites) (Fig. 3.2A), well after the reported onset of Gremlin expression at ~E9 (Benazet 
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et al., 2009; Zúñiga and Zeller, 1999). The enhancer had activity in the posterior limb 
within a subregion of the Shh-responsive domain. Shh expression initiates in the limb bud 
around 28 somites (E9.75) (Charité et al., 2000), and the lag in reporter expression is 
consistent with the reported kinetics of Shh-mediated induction of Gremlin (Benazet et al., 
2009).  By E10.5, β-galactosidase activity was strongly upregulated and persisted until late 
E11.5 (Fig. 3.2B,C). By E11.75 expression was reduced and had retreated from the distal 
limb mesenchyme (Fig. 3.2D). Expression was nearly absent by E12.0 except for faint 
staining in the proximal middle of the condensing digit mesenchyme (Fig. 3.2E). No 
expression was detected after E12.0, correlating with the termination of Shh activity in the 
limb (Echelard et al., 1993; Harfe et al., 2004). Although the enhancer analyses focused on 
forelimb expression, we observed similar domains in the hindlimbs (Fig. 3.1C). 
 
Figure 3.1: GRE1 enhancer activity. (A) Schematic showing the location of GRE1 in 
relation to the Gremlin locus and the GRE1LacZ transgenic construct. (B,C) GRE1LacZ+/- 
E10.5 forelimb and hindlimb stained for β-galactosidase. (D) Illustration of a forelimb 
indicating the level of sectioning with a dashed red line. (E,F) Cryosections of 
GRE1LacZ+/- E10.5 forelimb and hindlimb stained for β-galactosidase and nuclear fast red. 
Anterior (ant.), posterior (post.), dorsal (dor), and ventral (vent.).  
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Figure 3.2: GRE1 enhancer activity correlates temporally with Shh activity. (A-E) 
GRE1LacZ+/- forelimbs stained for β-galactosidase activity from days E10 – E12. The 
somite stage is indicated to the left of each image. Expression activity in the limb correlates 
with Shh expression in the limb bud (indicated by the bar in the center). ‘a.’, anterior; ‘p.’, 
posterior; black arrow indicates β-galactosidase. 
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3.3: GRE1 ACTIVITY IS REGULATED BY GLI 
To determine if GRE1 is responsive to Shh signaling, we examined enhancer 
activity at E10.5 in Shh gain and loss-of-function backgrounds. In contrast to wild-type or 
heterozygous littermates (Fig. 3.3A,A’), Shh-/-;GRE1LacZ+/- embryos had no detectable β-
galactosidase activity (6/6 embryos) and, consistent with previous studies, Gremlin gene 
expression was highly downregulated (Fig. 3.3B,B’) (Zúñiga and Zeller, 1999). We also 
examined expression by activating high levels of Hh signaling throughout the limb bud 
using a Cre inducible, dominant active allele, RosaSmoM2 (Jeong et al., 2004). 
Prx1Cre;RosaSmoM2c/+;GRE1LacZ+/- embryos expressed both the Gremlin transcript and β-
galactosidase activity throughout the entire distal limb bud (11/11 embryos; Fig. 3.3C, C’), 
indicating that high levels of Hh pathway activity were sufficient to activate GRE1LacZ 
along the anterior-posterior axis. Gremlin gene expression appeared patchy (Fig. 3.3C’), 
and while the reason for this expression in unclear, it is consistent with observations from 
another study that also activated the Hh pathway throughout the limb bud (Butterfield et 
al., 2009). Because PrxCre is active throughout the limb mesenchyme (Logan et al., 2002), 
the distal restriction of GRE1 enhancer activity suggested that additional, distal factors are 
also required for Gremlin expression. We concluded that Shh is both necessary and 
sufficient for enhancer activation.  
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Figure 3.3: GRE1 enhancer activity requires Gli-activation. E10.5 GRE1LacZ forelimbs 
indicating enhancer activity in various genetic backgrounds. The corresponding Gli 
gradient status (Gli-activator in black, Gli-repressor in red) is indicated to the right of each 
set of images. (A-E’) Embryos were dissected into halves, and the left forelimb (left 
column) was stained for enhancer activity (β-galactosidase) while the corresponding right 
forelimb (right column) was assayed for Gremlin gene expression. Limbs on the left appear 
larger than their contralateral right side due to differences in how they are fixed. The 
genotypes at the left correspond to (A-A’) Control (GRE1LacZ+/-), (B-B’) Shh-/-
;GRE1LacZ+/-, (C-C’) GRE1LacZ+/-,PrxCre+/-;RosaSmoM2c/+, (D-D’) Gli3-/-;GRE1LacZ+/-, 
(E-E’) GRE1LacZ+/-;Shh-/-;Gli3-/-.  ‘a.’, anterior; ‘p.’, posterior. 
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We next examined enhancer activity in Gli3-/-;GRE1LacZ+/- embryos at E10.5. 
Consistent with previous reports, Gremlin gene expression expands anteriorly in Gli3-/- 
embryos (Fig. 3.3D’). In contrast the enhancer activity domain, marked by β-galactosidase 
staining, does not expand anteriorly (Fig. 3.3D). Instead, the domain is significantly 
reduced in all Gli3-/- embryos (5/5) compared to heterozygous littermates (p = 0.0007). The 
reduction in enhancer activity suggests a role for Gli3 activator in the posterior limb. 
Consistent with this, Gli3-/- limbs at this stage had significantly reduced levels of the Gli 
activator target gene Gli1 (Fig. 3.4A). There was also a trend toward a 25% reduction in 
Shh levels that did not reach statistically significant levels (Fig. 3.4B). These results are 
consistent with previous studies that have shown that Gli3-/- limb buds have reduced Gli 
activator levels as a combination of the direct reduction in Gli3 activator and reduced levels 
of Shh (Bai et al., 2004; Galli et al., 2010; Wang et al., 2007).  
 
 
Figure 3.4: Gli1 is reduced in Gli3-/- forelimbs. qRT-PCR for (A) Gli1 and (B) Shh in 
pairs of forelimbs from wild-type and Gli3-/- embryos (32-34 somites), n=6 forelimb pairs 
per genotype. (A) Red asterisk indicates that Gli1 expression is significantly reduced in 
Gli3-/- forelimbs (Mann-Whitney U Test; U=1.000, p = 0.0087). (B) In the same samples, 
Shh levels tend to be reduced although not to statistically significant levels (Mann-Whitney 
U Test; U=6.000, p = 0.1255). The bars indicate the mean and standard error of the mean.  
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In Shh-/-;Gli3-/-;GRE1LacZ+/- embryos at E10.5, Gremlin expression persists in 
limb buds in a depolarized fashion as shown previously (Fig 3.3E’) (Aoto et al., 2002; 
Litingtung et al., 2002; te Welscher et al., 2002). However, the limb buds had an absence 
of β-galactosidase staining (3/3 embryos; Fig. 3.3E), indicating that Gli activation is 
required for GRE1 enhancer activity. This is consistent with our previous work that 
identified a Gli motif that was essential for driving enhancer activity (Vokes et al., 2008).  
 
3.4: GRE1 REQUIRES SUSTAINED SHH SIGNALING 
To determine the time period during which GRE1 requires Gli-activator for 
enhancer activity in the posterior limb, we used an established ex vivo limb bud culture 
assay, treating GRE1LacZ+/- limb buds with the Hh pathway inhibitor cyclopamine 
(Panman et al., 2006). We cultured one forelimb in media containing cyclopamine while 
the contralateral side was cultured in control media, providing an internal control for 
staging and embryo variability (Fig. 3.5B). As expected from the lack of activity in Shh-/- 
embryos (Fig. 3.3B), limb buds cultured in cyclopamine at stages before enhancer activity 
is detected (29-30 somites) resulted in a complete loss of -galactosidase (Figs. 3.5A, A’). 
In limb buds cultured at 31-32 somites, there is a strong reduction (61%) in the size of the 
enhancer activity domain when compared to the control side (Fig. 3.5C-C’’; p = 0.0004). 
Limbs cultured from 33-34 somites have more modest reductions (39%) in the size of the 
enhancer domain (Fig. 3D-D’’; p =0.0065).  The domain size no longer depends on Shh 
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signaling from 35-36 somites onwards (Figs. 3.5E-E’’ p = 0.3333). These results indicated 
that Shh signaling is required for expanding the domain of enhancer activity until 35-36 
somites.  
Since residual β-galactosidase protein could persist after the cessation of 
transcriptional activity from the reporter, it was not possible to determine if Shh is required 
to maintain enhancer activity with this approach. To circumvent this problem we performed 
additional limb bud cultures on 32 and 38 somite embryos and measured LacZ expression 
by qRT-PCR. As a control to ensure that the experimental conditions resulted in robust 
inhibition of Shh signaling, we measured the expression of the obligate Shh target gene 
Gli1 (Panman et al., 2006). When forelimbs from 32 somite embryos were cultured, they 
had an 84% reduction in Gli1 gene expression and a 75% reduction in LacZ expression. 
Similarly, forelimbs cultured from 38 somites embryos had a 70% reduction in Gli1 and 
also had a 64% reduction in LacZ (Fig. 3.5F). The change in gene expression at later stages 
contrasts with the stable expression domains indicated by -galactosidase staining (Fig. 
3.5E-E’’). We concluded that establishing the enhancer domain requires Shh signaling 
transiently until 35 somites, while enhancer activity within the domain continues to require 
sustained Shh signaling.  
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Figure 3.5: GRE1 enhancer activity requires sustained Shh signaling. GRE1LacZ+/- 
forelimbs were cultured in vehicle-containing control media (A-F) while their contralateral 
forelimbs were cultured in cyclopamine (A’-F’) as shown in (B). The stage of the limb 
buds at the start of the experiment is indicated on the left. (C’’-E’’) Graphs indicating the 
domain size measured by the ratio of the β-galactosidase stained area to the total limb bud 
area for control (black) or cyclopamine treated (red) limb buds. Data points indicate the 
median and range of values. The presence of an asterisk indicates statistically significant 
difference (Mann-Whitney U test). Specific values are: C’’ U=3.5, p =0.0004; D’’ U=1.5, 
p = 0.0065; E’’ U=7.5, p = 0.3333. qRT-PCR in GRE1LacZ+/- cultured forelimbs (as shown 
in (B). Error bars indicate the standard error of mean, ‘a.’, anterior; ‘p.’, posterior. 
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3.5: WNT AND FGF SIGNALING DO NOT REGULATE GRE1 
Previous work demonstrate that FGF signaling represses Grem1 expression in the 
anterior-distal limb (Verheyden and Sun, 2008). In addition to requiring Hh signaling, 
GRE1 could potentially be negatively regulated by FGF signaling. To test this, we cultured 
GRE1LacZ limb buds in the presence and absence of the FGF inhibitor, SU5402 
(Mohammadi et al., 1997). Consistent with previous results, inhibiting FGF signaling 
resulted in the expansion of Gremlin into the distal-anterior limb (Fig. 3.6E,F); however, 
GRE1LacZ activity did not expand into the distal-anterior limb (Fig. 3.6A-D). We conclude 
that FGF signaling does not negatively regulate GRE1.   
In addition, another possibility is that WNT signaling may play a role in regulating 
GRE1.  To test this, we cultured GRE1LacZ limb buds in control media or media containing 
a WNT inhibitor, IWR1 (Chen et al., 2009).  After 15 hours in culture, the mRNA level of 
the WNT target gene, Axin2, was downregulated in limbs cultured in IWR1 (Fig. 3.7C). 
However, the expression level of LacZ mRNA was not changed between control and IWR1 
treated cultures. In addition, the β-galactosidase expression domain for GRE1LacZ did not 
change between control or IWR1 treated cultures (Fig. 3.7A,B). Under our experimental 
conditions, we conclude that WNT signaling does not regulate the activity of GRE1. 
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Figure 3.6: GRE1 enhancer activity is not negatively regulated by FGF. E11.5 
GRE1LacZ+/- forelimbs (45-48 somites) were cultured in vehicle-containing control 
media (0.1% DMSO) (A) while their contralateral forelimbs were cultured in 10μM 
SU5402 8 hours (B) and stained for β- galactosidase activity. The normalized distance of 
the β-galactosidase domain from the distal (C) and anterior (D) limb (schematized as red 
lines in (A)) is not significantly altered in SU5402- treated embryos (Mann Whitney U 
Test). Horizontal lines indicate the mean and standard error of mean. (E,F) Consistent with 
previous reports, inhibiting FGF signaling results in an increase in distal anterior Gremlin 
expression (n=2). (G,H) Contralateral hindlimbs from the same embryos shown in panels 
A and B show a reduction in the FGF target gene Sprouty4 in SU4202 cultured limb buds 
(H) compared to contralateral limb buds cultured in control media (G). Images A,B,G,H 
are from a 48 somite embryo. Images E,F are from a 45 somite embryo. 
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Figure 3.7: Inhibition of WNT signaling does not perturb GRE1 activity. E10.25 (32-34 
somites) GRE1LacZ+/- forelimbs were cultured in vehicle-containing control media (0.1% 
DMSO) (A) while their contralateral forelimbs were cultured in 1 μM IWR1 (WNT 
inhibitor) for 15 hours (B) and stained for β- galactosidase activity. (C) qRT-qPCR for 
Axin2 and LacZ expression. Gene expression normalized to Gapdh in the wild-type sample.
   
 
3.6: GRE1 FUNCTIONS AS A GLI-MEDIATED SILENCER 
We generated mice containing a deletion of GRE1 (described in Appendix C). 
Gremlin∆GRE1/∆GRE1 forelimbs expressed Gremlin and Formin at levels that are 
indistinguishable from wild-type control forelimbs (Fig. 3.8A-C). Gremlin∆GRE1/∆GRE1 mice 
were viable and fertile with normal skeletal patterning (Fig. 3.8D-G). Embryos containing 
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one null allele of Gremlin (Khokha et al., 2003) and a second allele harboring the deletion 
of GRE1 also had normal skeletal patterning (Fig. 3.9A,B). These results indicate that 
GRE1 is not necessary for normal skeletal development. The Gremlin gene expression 
domain was nearly normal in Gremlin∆GRE1/∆GRE1 embryos at E11 (Fig. 3.8A,B) but at 
earlier stages, the distal anterior boundaries of expression were more diffuse (Fig. 
3.10A,B). In light of these results, we hypothesized that redundant Gli-dependent CRMs 
might regulate Gremlin. Two additional Gli-binding regions are present within the Gremlin 
locus (Vokes et al., 2008). One of these regions was recently shown to have Shh-responsive 
enhancer activity and to be critical for mediating BAC reporter activity in transgenic 
embryos (Zuniga et al., 2012). We hypothesized that our Gli CRM might be redundant with 
other GREs under normal conditions but still required for robust regulation of Gremlin. 
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Figure 3.8: GRE1 is not essential for limb development. (A,B) Gremlin expression in 
forelimbs at E11 (41 somites). (C) Gremlin∆GRE1/∆GRE1 embryos express Gremlin and 
Formin at levels that are statistically indistinguishable from wild-type embryos (One 
Sample T-Test, Two Tails; Gremlin p = 0.1172; Formin p =0.4548). Values are normalized 
to the distal marker Jagged 1. Error bars represent standard error of mean from four 
independent biological samples (E10.5, 34-37 somites). (D-G) E18.5 skeletal preparations 
showing forelimbs and hindlimbs of the indicated genotypes. ‘a.’, anterior; ‘p.’, posterior. 
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Figure 3.9: Gremlin and GRE1 transheterozygote displays normal limb patterning. (A) 
Embryos containing a null allele of Gremlin (Grem1tm1Rmh) and the other allele with a 
deletion of GRE1 have normal limb skeletal patterning. (B-E) Forelimbs and hindlimbs 
from the same embryo at E18.5 stained for bone (Alizarin Red) and cartilage (Alcian Blue). 
The numbers of skeletons that were analyzed for each genotype: (A) n=6, (B) n=3, (C) 
n=4, (D) n=4 
 
Studies in Drosophila have tested the robustness of transcriptional responses to 
shadow enhancers by examining CRM deletion phenotypes at the outer ranges of 
permissive temperatures or by removing one copy of an upstream regulator (Frankel et al., 
2010; Perry et al., 2010). We used the latter strategy to examine Gremlin expression in 
Gremlin∆GRE1/∆GRE1 embryos containing a single copy of Gli3, which is sufficient to prevent 
the distal-anterior expression of Gremlin seen in Gli3-/- embryos (te Welscher et al., 2002). 
At E10.5, both wild-type and Gli3+/- littermates have a sharp boundary of Gremlin 
expression that is restricted from the most distal-anterior mesoderm in the forelimbs (n=7; 
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brackets in Fig. 3.10A,C). Gremlin∆GRE1/∆GRE1 littermates have forelimbs with less 
pronounced distal-anterior borders of Gremlin and with weak ectopic expression in the 
anterior limb mesoderm directly adjacent to the apical ectodermal ridge (n=10; dashed 
arrow in Fig. 3.10B). In contrast, Gremlin∆GRE1/∆GRE1;Gli3+/- littermates have forelimbs 
with ectopic distal-anterior Gremlin expression that is broader and stronger than in 
Gremlin∆GRE1/∆GRE1 forelimbs (n=8; Fig. 3.10D). This expression is significantly different 
from Gli3+/- (p = 0.0002) or Gremlin∆GRE1/∆GRE1 forelimbs (p<0.0001), indicating a genetic 
interaction between Gli3 and the Gremlin∆GRE1 allele.  
 
 
Figure 3.10: The GRE1 CRM interacts genetically with Gli3 to repress Grem1. Grem1 
expression in various genetic backgrounds in the forelimbs of 35-36 somite embryos (A-
D) and hindlimbs of 37-38 somite embryos (E-H). The white brackets in panels (A,C) 
indicate the Gremlin free domain in anterior limb buds. White arrows (B,D,H) indicate 
ectopic distal-anterior Gremlin expression in Gremlin∆GRE1/∆GRE1 backgrounds. (I-P) E18.5 
skeletal preparations of the hand (J-L) or foot (M-P) in various genetic backgrounds. The 
arrowhead (K) highlights a bifurcated thumb; the asterisks (L,P) indicate polydactyly. 
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An expansion of Gremlin protein into the anterior distal mesenchyme would inhibit 
BMPs, causing an expansion in anterior growth (Lopez-Rios et al., 2012; Pizette and 
Niswander, 1999). This growth would likely result in anterior polydactyly, which is also 
seen in mice with reduced BMP activity (Dunn et al., 1997; Selever et al., 2004). In the 
mixed genetic background present in our colony, the presence of the Gli3+/- ‘extra toes’ 
allele only rarely results in mice or embryos with fully polydactylous digits. In this study, 
all of the Gli3+/- embryos had a single nub (a fleshy outgrowth that sometimes contains a 
single speck of cartilage) but none of them had distinct polydactylous digits (18/18 
hindlimbs) (Fig. 3.10O). Gremlin∆GRE1/∆GRE1 littermates have normal digit patterning 
(14/14 hindlimbs) (Fig 3.10N). In contrast, Gremlin∆GRE1/∆GRE1;Gli3+/- littermates have a 
distinct, polydactylous digit in 3/8 hindlimbs (Fig. 3.10P), a significant difference from 
Gli3+/- embryos alone (p =0.0215). Gli3+/- forelimbs displayed a spectrum of phenotypes 
ranging from completely normal digits (7/17) to polysyndactyly (4/17). 
Gremlin∆GRE1/∆GRE1;Gli3+/- forelimbs uniformly contained a polysyndactylous thumb (8/8), 
a significant increase in frequency compared to Gli3+/- embryos (p = 0.0005; Figs. 4.10I-
L). Gremlin∆GRE1/+;Gli3+/- embryos also contained a high proportion of polysyndactylous 
forelimbs (23/28). These results suggest that GRE1 has silencer activity that is required for 
robust anterior repression of Gremlin. Our result is consistent with previous studies 
showing a genetic interaction between Gli3 and BMP4 (Dunn et al., 1997; Lopez-Rios et 
al., 2012). We concluded that silencer activity through GRE1 is required for robust, Gli-
dependent repression of Gremlin in the anterior limb (schematized in Fig. 3.11A-D).  
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Figure 3.11: Schematic models showing how Gli3 repression of Grem1 (blue crescent) 
might occur in various genetic backgrounds.   
 
3.7: DISCUSSION 
In this study we have performed the first genetic characterization of a vertebrate 
Gli CRM. Within the limb bud, most putative Gli target genes are associated with multiple 
Gli binding regions (Vokes et al., 2008). Our results, suggest that one role for multiple, 
distinct Gli binding regions around Gli target genes is to provide a robust silencing 
response that buffers against genetic perturbations. This contrasts with the Fgf8 and HoxD 
loci where multiple enhancers with similar activity domains have been proposed to 
additively or synergistically amplify transcription (Marinic et al., 2013; Montavon et al., 
2011). Our results further suggest that Gli silencers prevent transcriptional activity driven 
by additional, Gli-independent CRMs. We also show that GRE1 can act as a Gli-activator 
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dependent enhancer in the posterior limb although the biological role for this activity is 
unclear (see section on Gli enhancer activity).  
We propose a model where Gli repressors bind to multiple Gli-dependent CRMs in 
the anterior limb, providing a robust silencing activity that prevents ectopic activation of 
Gremlin that would otherwise be driven by at least one additional Gli-independent CRM 
that is active throughout the distal limb (a pan-limb enhancer).  Gli repressor-mediated 
silencing results in the anterior repression of Gremlin in the absence of threshold levels of 
Gli activator complexes. In the posterior limb, where Gli activator activity is high and Gli 
repressor activity is low, GRE1 silencing activity is lost and Gli-activator complexes 
provide enhancer activity. We have synthesized these results in a model for how Gremlin 
is regulated by Gli proteins within the limb (Fig. 3.11). 
 
3.7.1: GRE1 enhancer activity 
GRE1 enhancer activity is detected in the posterior limb in a spatial and temporal 
fashion that correlates with Shh signaling (Fig. 3.2). GRE1 requires Gli-activation for 
initiating and sustaining activity at E10.5 and ectopic Gli activator signaling is sufficient 
to drive GRE1 expression throughout the anterior-posterior axis (Fig. 3.3).  These results 
suggest that GRE1 enhancer activity is primarily regulated by Shh signaling.  GRE1 
enhancer activity is transiently reduced in E10.5 Gli3-/- limb buds (Fig. 3.3D). Our own 
results are consistent with several studies showing that Gli3-/- limbs have reduced levels of 
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Gli activation caused by a combination of reduced levels of Gli proteins and a reduction in 
Shh  (Bai et al., 2004; Bowers et al., 2012; Galli et al., 2010; Wang et al., 2007).  
In marked contrast to Gremlin gene expression, the GRE1 enhancer domain does 
not expand in E10.5 Gli3-/- limb buds  (Fig. 3.3D,D’’). We rule out the trivial possibility 
that Gli repressors do not work through GRE1 because our subsequent experiments 
indicate that it does indeed mediate Gli repressor-mediated silencing of Gremlin, and it is 
bound by Gli3 repressor in chromatin immunoprecipitation assays (Vokes et al., 2008). 
The behavior of GRE1 contrasts with the behavior of a Dpp wing imaginal disc CRM in 
Drosophila, where both repressor and activator functions of Ci can be detected out in the 
same enhancer element (Muller and Basler, 2000). Within the mammalian neural tube, 
studies have reported conflicting conclusions regarding the role for Gli3 in restricting the 
boundaries of Gli activator enhancers or genes (Balaskas et al., 2012; Oosterveen et al., 
2012; Peterson et al., 2012).   
There are several possible explanations for the lack of anterior expansion of 
GRE1LacZ in E10.5 Gli3-/- limb buds. The first is that Gli repressors might not compete 
with Gli activators to limit the anterior domain of enhancer activity. In this scenario, 
enhancer activity is driven solely by threshold-dependent Gli activation. The lack of 
baseline anterior activity would prevent visualization of the silencer activity in an enhancer 
reporter assay. A second possibility is that the GRE1LacZ transgenic construct is incapable 
of responding normally to Gli repressors because it is removed from its normal 
chromosomal environment. Indeed, our experiments suggest that Gli repressors do regulate 
the activity of additional CRMs in the Gremlin locus. Taken out of context, GRE1 could 
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also have altered affinities for Gli activator and repressor complexes that prevent its 
anterior expansion in Gli3-/- embryos. A third possibility is that residual Gli repressor 
activity is sufficient to prevent anterior expansion of GRE1LacZ in Gli3-/- limb buds. 
Consistent with this, recent work has indicated that there is a genetic role for Gli2 repressor 
in skeletal patterning in the absence of Gli3 (Bowers et al., 2012). However, Gremlin 
expression appears largely symmetrical along the anterior-posterior axis in Gli3-/- limb 
buds, suggesting that the remaining Gli repressor activity mediated by Gli2 might not be 
sufficient to repress Gremlin  (Fig. 3.3D’) (Aoto et al., 2002; Litingtung et al., 2002; te 
Welscher et al., 2002). Additional studies examining GRE1LacZ enhancer activity in Gli2-
/-;Gli3-/- limb buds would be necessary to determine if GRE1 itself is more sensitive to Gli2 
repression than the overall Gremlin gene expression pattern would suggest.  
 
3.7.2: GRE1 and GLI repressors 
Two models for Gli repression have been proposed (Wang et al., 2010). In one, 
Gli3 repressor acts as an inert decoy competing with Gli activator to regulate the 
transcription of target genes (Oosterveen et al., 2012; Wang et al., 2010). In the second, 
Gli repressor behaves like a conventional transcriptional repressor, recruiting 
transcriptional co-repressors that actively shut down transcription (Wang et al., 2010). 
While the first model would apply specifically to Gli activator target genes, the second 
model could in principle apply to both Gli activator target genes and to genes that only 
require Gli derepression. GRE1 displays properties that are associated with both classes of 
 65 
Gli target genes.  Gremlin is a Gli derepression gene and Gli3 works through GRE1 as a 
silencer, preventing transcription directed by additional CRMs that would otherwise lead 
to ectopic distal-anterior expression. This mechanism of repression is distinct from 
conventional CRMs where repressor activity is integrated at the CRM level with each CRM 
then acting as an autonomous module to regulate gene expression. In future studies, it will 
be interesting to determine the mechanism of repression, which could function as a basal 
regulator of transcriptional activity. Alternatively Gli3 might specifically inactivate one or 
more CRMs.  
 
3.7.3: GLI proteins generate asymmetric gene expression  
In the posterior limb bud, it is unclear whether Gli activators are simply indicative 
of a de-repressed environment that permits additional CRMs to drive expression or if they 
also provide a quantitative contribution as enhancers to increase Gremlin transcription. The 
only evidence suggesting GRE1 is an enhancer is the enhancer activity of the isolated 
element in transgenic limb buds (Fig. 3.2).  While this fits the generally accepted criteria 
for an enhancer, there is no genetic evidence for reduced Gli activator responses in either 
Gremlin∆GRE1/- or Gremlin∆GRE1/∆GRE1;Shh+/- embryos (Fig. 3.9, data not shown).  
The lack of any detectable phenotype suggests that in the context of the native 
genomic locus, the enhancer activity is absent, trivial or completely redundant with 
additional Gli-dependent CRMs. The ambiguity over the contribution of enhancer activity 
is represented in Fig. 3.12, suggesting that the major purpose of GRE1 enhancer activity 
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lies in counteracting Gli repression rather than providing quantitative levels of activation. 
In this way, GRE1 could act as a binary switch, causing transcription to be on or off in 
different domains (Fig. 3.12). This model provides a mechanism for how Shh signaling 
imposes asymmetric expression of ‘pre-patterned’ genes that would, in the absence of any 
Gli regulation, be symmetrically expressed throughout the limb bud. It also suggests that 
the inclusion of Gli-driven CRMs into the locus of pre-patterned limb might have provided 
an evolutionary mechanism for regulating asymmetric gene expression in a pre-existing 
pattern. 
 
3.7.4: Multiple CRMs regulate Grem1 
Within the context of this study, there appear to be at least three distinct CRMs 
regulating Gremlin. This is consistent with previous studies that describe a complex 
regulatory locus for Gremlin (Vokes et al., 2008; Wang et al., 1997; Zuniga et al., 2012; 
Zuniga et al., 2004). Several proteins have also been shown to regulate Gremlin at various 
developmental time points. In particular, BMPs and HoxA/D transcription factors both 
regulate Gremlin along the anterior-posterior axis. Their activity and expression domains 
make them excellent candidate regulators for the Gli-independent pan-limb enhancer (Fig. 
3.12) (Benazet et al., 2009; Capdevila et al., 1999; Nissim et al., 2006; Sheth et al., 2013). 
Intriguingly, HoxA/D conditional mutants lack most Gremlin expression with the 
exception of a posterior domain that appears nearly identical to the Gli CRM enhancer 
domain (Fig. 3.1B) (Sheth et al., 2013). Although our model depicts pan-limb enhancer 
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activity with one CRM as the simplest possibility (Fig. 3.12), it is certainly possible that 
this activity integrates multiple Gli-independent enhancers active in distinct or overlapping 
domains. 
 
Figure 3.12: Gli proteins generate asymmetric expression of Gremlin. Gremlin is activated 
by a pan-limb enhancer (blue circle) that has activity throughout the distal limb. In genetic 
backgrounds where there is an absence of Gli regulation (no activation or repression, e.g. 
Shh-/-;Gli3-/-), the pan-limb enhancer drives symmetrical expression of Gremlin throughout 
the limb bud. In the posterior region, Gli-activators regulate redundant Gli-dependent 
CRMs, including GRE1, causing a loss of Gli-mediated silencing and possibly threshold-
dependent enhancer activity (indicated by dashed arrows). In the anterior region, GRE1 
acts as a silencer, preventing ectopic activation of Gremlin through a pan-limb enhancer. 
The additional Gli-dependent CRM(s) could be either directly or indirectly regulated by 
Gli signaling. 
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Recently, a second GRE that lies closer to the transcriptional start site has been 
characterized. While it does not contain a high affinity Gli motif within the core region, it 
is nonetheless bound by Gli3 in ChIP assays and requires Shh expression for enhancer 
activity in mutant embryos (Zuniga et al., 2012). Unlike GRE1, the more proximal GRE is 
essential for Gremlin transcriptional activity in the same BAC reporter used in this study 
(Zuniga et al., 2012). Notably, GRE1 is not sufficient to activate transcriptional activity in 
its absence. This more proximal GRE could integrate Gli signaling with additional, Shh-
independent, facets of Gremlin or there could be additional, uncharacterized Gli-dependent 
element(s). Our study was limited to the contribution of a single CRM, and future studies 
will be required to determine if there are higher-order chromatin interactions among the 
individual CRMs regulating Gremlin as has been suggested for the Fgf8 and HoxD loci 
(Marinic et al., 2013; Montavon et al., 2011). In Drosophila, Ci (Gli) repressors have been 
proposed to work cooperatively by binding to several distinct sites within a CRM 
regulating Dpp (Parker et al., 2011). The presence of an additional Gli CRM in the Gremlin 
locus raises the intriguing possibility that Gli proteins binding to distinct CRMs might 
nonetheless be able to cooperatively repress Gremlin in the context of a higher order 
chromatin structure. 
 
3.7.5: GLI-bound CRMs confer robust transcriptional control  
Embryos and mice lacking GRE1 have no detectable skeletal phenotype. 
Nonetheless, embryos do have subtle shifts in Gremlin expression (Fig. 3.10A,B), and 
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when one copy of Gli3 is removed GRE1 is required for the repression of Gremlin. It is 
formally possible that the enhanced phenotype seen in ΔGRE1;Gli3 compound 
heterozygous embryos (Fig. 3.10) is due to the presence of another allele co-segregating 
with GRE1. The primary support that this interaction occurs between GRE1 and Gli3 is 
that is consistent with interactions observed between Gli3 and BMPs (which should have 
reduced anterior activity with ectopic Gremlin expression) (Dunn et al., 1997; Lopez-Rios 
et al., 2012).  
Both the subtle changes in expression pattern and the requirement of the CRM as a 
mechanism for buffering genetic variation are analogous to the shadow enhancers 
described in Drosophila (Barolo, 2012; Frankel et al., 2010). Shadow elements are defined 
by the genetic interactions of two genetically defined CRMs (Frankel, 2012) and further 
genetic studies involving multiple Gli bound elements would be required to determine if 
the Gli CRM is functioning as a shadow repressor of Gremlin. Our study, focused 
exclusively on a single Gli CRM, is the first to address the potential genetic role that 
multiple Gli-bound CRMs play in regulating transcription. Multiple Gli binding sites are 
associated with many predicted Gli target genes (Peterson et al., 2012; Vokes et al., 2008) 
and we propose that they may act as a general mechanism for mediating robust 
transcriptional responses to Hh signaling.  
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Chapter 4: Manipulating gene expression in dissociated limb buds 
 
Portions of this chapter are modified with permission from the authors.  Lewandowski, 
J.P., Pursell, T. A., Rabinowitz, A. H., & Vokes, S. A. Manipulating gene expression and 
signaling activity in cultured mouse limb bud cells. Dev. Dyn. (2014) 243(7):928-936. 
J.P.L., T.P., conceived and performed experiments, and interpreted data; A.R., 
performed experiments.  
 
4.1: INTRODUCTION 
The developing vertebrate limbs provide a system to study cell differentiation, 
tissue morphogenesis, and the integration of signaling pathways.  Decades of research have 
established a broad framework of the major pathways required during limb bud 
development, using a combination of genetic and embryological methods (Rabinowitz and 
Vokes, 2012). However, a major limitation of current genetic approaches is that testing 
gene function or DNA regulatory element activity is time consuming and resource-
intensive, often requiring the generation of genetically modified embryos.  Methods 
allowing a faster way to evaluate gene function and DNA regulatory elements would 
significantly improve the utility of the limb bud system.  
 Cell culture approaches are a way to fulfill this need; however, there are no broadly 
used cell lines that represent limb bud mesenchyme. A few immortalized limb bud 
mesenchyme cell lines have been generated (Trevino et al., 1993); these represent distinct 
types of mesenchyme but have not been extensively characterized.  Cell lines derived from 
related lineages can differentiate into bone or cartilage (Denker et al., 1995; Long et al., 
2004) but it is unclear to what extent they represent limb bud cells. Also, cultures of 
primary limb bud cells grown under standard conditions quickly differentiate into 
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chondrocytes, limiting their usefulness for studying limb bud development. In a significant 
advance two recent studies have shown that chicken limb bud cells, cultured in the presence 
of WNT3a and FGF8, express distal limb bud mesenchyme gene markers and remain 
undifferentiated (ten Berge et al., 2008; Cooper et al., 2011).  
 Using these studies as a foundation, we describe a method for culturing murine 
E10.5 limb bud cells in micromass-like conditions on a 96-well format.  We then describe 
a method to deliver plasmids and siRNAs at high efficiency that result in quantifiable 
changes to endogenous gene expression. We specifically adapt these conditions to assay 
Hedgehog (Hh)-responsive gene expression. Furthermore, we show that this approach is 
readily amenable to study the response of other signaling pathways such as WNT and BMP 
that are also active in limb bud mesenchyme. 
 
4.2: ASSESSMENT OF DIFFERENTIATION IN DISSOCIATED LIMB CELL CULTURES 
Cultures of primary limb bud cells containing different signaling factors have 
successfully been used to prevent cell differentiation, allowing limb cells to be cultured as 
a progenitor population for several days (ten Berge et al., 2008; Cooper et al., 2011). 
Treatment with FGF8 alone can delay differentiation for 4 days while co-treatment with 
WNT3a essentially blocks further differentiation (ten Berge et al., 2008). Additional 
studies suggest that FGFs provide a distalizing influence on the limb (Rosello-Diez et al., 
2011). We used these conditions as a foundation for culturing mouse forelimb cells. Limb 
buds from E10.5 (33-36 somites) mouse embryos were harvested and processed in 
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electroporation solution only, and  post electroporation approximately 200,000 cells were 
plated per well on a 96-well half-area plate.  
As an initial experiment, we cultured cells in media containing FGF8 and 
purmorphamine, a small molecule that constitutively activates the Hedgehog (Hh) pathway 
by binding to Smoothened (Sinha and Chen, 2006; Dessaud et al., 2007). We then stained 
cultures with Alcian blue to mark chondrocytes, and also examined genes expressed during 
chondrogenesis. As expected, at 72 hours Alcian blue staining was observed in cartilage 
forming nodules produced by limb cells cultured in control media (Fig. 4.1A). In contrast, 
little or no Alcian blue staining was observed in limb cells cultured in media containing 
FGF8, purmorphamine, or FGF8 and purmorphamine (Fig. 4.1B-D), suggesting that these 
conditions block cartilage formation.  
While Alcian blue staining is indicative of cartilage formation, we also quantified 
differentiation by using quantitative reverse transcription PCR (qRT-PCR) to determine 
the expression of Sox9, an early marker of chondrocyte differentiation, as well as Aggrecan 
1 (Agc1), a chondrocyte-specific marker (Bi et al., 1999; Akiyama et al., 2002). We 
normalized gene expression to the 24 hour control sample in order to examine changes in 
gene expression over time. In addition, we compare these normalized data to the relative 
gene expression values from freshly isolated limb buds. When compared to control 
cultures, Sox9 expression was moderately reduced at all time points in cells cultured in 
media containing FGF8, purmorphamine, and FGF8 and purmorphamine (Fig. 4.1E). The 
modest reduction in Sox9 likely occurs because proximal expression has already initiated 
in E10.5 limb buds (Kawakami et al., 2005). Agc1 is strongly activated in control cultures 
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while cells cultured in media containing FGF8 or purmorphamine had greatly reduced 
levels of Agc1, suggesting a delay in differentiation (Fig. 4.1F).  Cells cultured in media 
containing both FGF8 and purmorphamine had essentially no Agc1 expression (mean 
expression value = 0.333 at 72 hours) (Fig. 4.1F).  To note, Agc1 is not robustly detected 
in freshly isolated limb buds.  Combined, our data indicate that limb bud cells cultured in 
media containing FGF8, purmorphamine, or the combination of FGF8 and purmorphamine 
prevent chondrogenic differentiation during the 3-day period of our assay.  
 
Figure 4.1: Limb bud cells cultured with FGF8 and purmorphamine do not differentiate. 
(A-D) Primary limb bud cell cultures at 72 hours stained with Alcian blue. Cells in control 
media (A) show nodules stained with Alcian blue, while cells cultured in 150 ng/mL FGF8-
containing media (B), 5µM purmorphamine (PM) (C) or FGF8 and PM (D) have minimal 
or no Alcian blue staining. Cells are shown at the same magnification (10x), and the scale 
bar is 200 µm. (E,F) qRT-PCR for chondrogenic markers in limb cell cultures at 24, 48, 
and 72 hours. Gene expression is normalized to Gapdh in the control sample at 24 hours, 
and comparison to freshly isolated limb cells is shown with a gray open square. Data points 
are the mean of 3 independent experiments and error bars represent the s.e.m. 
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4.3: PURMORPHAMINE PROMOTES AN INCREASE IN CELL NUMBER 
Previous studies using WNT3a alone or in combination with FGF8 demonstrated 
that both are effective to promote an increase in cell number in chick limb bud cultures (ten 
Berge et al., 2008). We performed cell counts at 24, 48, and 72 hours to determine the 
individual and collective effect of FGF8 and purmorphamine on cell number during the 3-
day culture period (Fig. 4.2A).  Consistent with previous reports (ten Berge et al., 2008), 
FGF8 alone was not effective in promoting an increase in the number of cells over time. In 
contrast, cells cultured in purmorphamine alone or FGF8 and purmorphamine caused an 
increase in the number of cells, although not to the extent as WNT3a or the combination 
of WNT3a and FGF8 (Fig. 4.2A).  In contrast, cells cultured in BMP4 had no increase in 
the number of cells.  We conclude that treatment with purmorphamine or the combination 
of FGF8 and purmorphamine promotes an increase in cell number.   
 
 
Figure 4.2: Individual and collective effects on cell number. (A) Effect of FGF8, 
purmorphamine (PM), both PM and FGF8, WNT3a (250 ng/mL), WNT3a and FGF8, and 
BMP4 (50 ng/mL) on limb cell number. PM alone and PM with FGF8 promote an increase 
in the number of limb mesenchyme cells in culture (red circle and blue diamond). Limb 
bud indicates number of cells initially plated. Data points are the mean of 5 independent 
samples and error bars indicate the s.e.m. 
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4.4: CULTURED LIMB CELLS ARE RESPONSIVE TO MULTIPLE SIGNALING PATHWAYS 
Since the cells are cultured with FGF8 and FGF signaling in the AER maintains 
Shh expression in limb buds (Laufer et al., 1994; Niswander et al., 1994; Bastida et al., 
2009), it was feasible that FGF8 could maintain endogenous Shh expression in our system. 
Compared to control cells, FGF8-treated cells have a mild upregulation of the FGF target 
gene Dusp6 (Kawakami et al., 2003; Mariani et al., 2008) (Fig. 4.3C); however, Shh 
expression is rapidly lost in FGF8 treated cells (Fig. 4.3B). We conclude that under our 
experimental conditions, limb bud cells cultured in purmorphamine or FGF8 and 
purmorphamine do not enhance endogenous Shh expression. 
Next, we next determined the ability of the cultured cells to respond to additional 
signaling pathways that are active in the limb mesenchyme.  We treated cells with BMP4 
or WNT3a and quantified induction by determining the gene expression levels for the target 
genes, Msx2 (Pizette et al., 2001) and Axin2 (ten Berge et al., 2008), respectively.  At 24 
hours BMP4 induced high levels of the Msx2, approximately 25 fold, and expression 
decreased to approximately 7 fold by 72 hours (Fig. 4.3D). WNT3a induced expression of 
the obligate target gene, Axin2, approximately 5 fold (Fig. 4.3E).   
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Figure 4.3: Cultured limb bud cells are responsive to multiple signaling pathways. (A-F) 
qRT-PCR for signaling pathway genes and chondrocyte differentiation markers. Note that 
Shh expression is highly downregulated in culture conditions (A). FGF8 signaling to cells 
shows a modest upregulation of Dusp6 in FGF8, and PM with FGF8 cultures (B). Culturing 
cells in the presence of BMP4 (C) or WNT3a (D) upregulates obligate target genes, Msx2 
(C) and Axin2 (D). WNT3a suppresses markers for chondrogenic differentiation, Sox9 and 
Agc1 (E,F). BMP4 treatment shows a downregulation of Sox9 over time (E) and an 
upregulation of Agc1 over time (F). Gene expression is normalized to Gapdh in the control 
sample at 24 hours, and comparison to freshly isolated limb cells is shown with a gray open 
square. Data points are the mean of 3 independent experiments and error bars represent the 
standard error of the mean. 
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We assessed the chondrogenic differentiation status of cells cultured in BMP4 and 
WNT3a by examining Sox9 and Agc1 expression. BMP4 treated cells at 24 hours showed 
similar levels of Sox9 to the control culture; however, at 72 hours Sox9 expression 
decreased (Fig. 4.3F). WNT3a alone or in combination with FGF8 treated cells showed a 
decrease in Sox9 expression at all the time points (Fig. 4.3F), which is consistent with 
previous reports (ten Berge et al., 2008). The chondrocyte-specific marker, Agc1, was 
expressed in BMP4 treated cells to levels similar observed in the control cells.  In contrast, 
cells cultured in WNT3a alone or with FGF8 had essentially no Agc1 expression (mean 
expression value = 0.03 and 0.173, respectively) (Fig. 4.3G). The inhibition of Agc1 is 
comparable to that observed in cells treated with both purmorphamine and FGF8 (Fig. 
4.1F).    Taken together, our data demonstrate that cells treated with both purmorphamine 
and FGF8 are maintained in an undifferentiated state similar to that previously reported for 
WNT3a alone and WNT3a and FGF8. 
 
4.5: EXPRESSION OF GLI TARGET GENES IN DISSOCIATED LIMB CELL CULTURES 
After adding purmorphamine, we sought to determine if limb bud cells were 
responsive to Hh  signaling. We quantified the level of Hh-induced gene expression during 
the culture period using qRT-PCR.  Expression of the obligate Hh target genes, Gli1 and 
Ptch1 (Marigo et al., 1996; Litingtung et al., 2002; te Welscher et al., 2002), were 
persistently upregulated at 24, 48, and 72 hours in limb cells cultured in media containing 
purmorphamine with or without FGF8 (Fig. 4.4A,B). In contrast, limb cells cultured in 
 78 
media containing FGF8 alone did not show an induction of Gli1 or Ptch1 (Fig. 4.4A,B).  
We conclude that under our experimental conditions, limb bud cells cultured in 
purmorphamine either with or without FGF8 elicit similar activation of the Hh pathway. 
We then examined the response of a broader group of Shh target genes: HoxD13, 
Grem1, Jag1, and Hand2 (Chiang et al., 2001; Panman et al., 2006; Vokes et al., 2008; 
Benazet et al., 2009).   Two genes, Jag1 and HoxD13, were upregulated in response to Hh 
signaling while Grem1 and Hand2 did not show a strong upregulation in either cultures 
treated with purmorphamine or FGF8 and purmorphamine (Fig. 4.4C-F). A plausible 
explanation for the lack of Hh-responsiveness observed for Grem1 is that in contrast to 
HoxD13, Grem1 has an early and transient requirement for Shh signaling (Panman et al., 
2006). Shh is expressed in E10.5 limb buds; therefore, this results in the prior activation of 
these genes before the limb cells are cultured. Taken together, our results suggest that 
determining the endogenous response of many Shh targets is limited in our current system 
using E10.5 limb buds (see Summary). 
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Figure 4.4: Regulation of Shh target genes in primary limb bud cultures. (A-F) qRT-PCR 
for Shh target genes at 24, 48, and 72 hours. Shh pathway target genes, Gli1 (A) and Ptch1 
(B) are expressed at high levels in media containing purmorphamine (PM) and media 
containing both FGF8 and PM.  Shh target genes, Jag1 (C) and HoxD13 (D), are 
upregulated in cultures with PM and both PM and FGF8.  Hand2 (E) and Grem1 (F) do 
not show a strong upregulation with PM or both PM and FGF8. Gene expression is 
normalized to Gapdh in the control sample at 24 hours, and comparison to freshly isolated 
limb cells is shown with a gray open square. Data points are the mean of 3 independent 
experiments and error bars represent the standard error of the mean. 
 80 
4.6: DELIVERING PLASMIDS AND SIRNA INTO LIMB CELL CULTURES 
Next, we sought to optimize conditions for delivering nucleic acids into cultured 
limb cells.  Ideally, we wanted to deliver both plasmids and siRNA at high efficiency using 
low cell numbers, which would allow this system to be used in a medium-throughput 
format (Fig. 4.5A). We utilized a 96-well electroporation device (Lonza) and optimized 
conditions, determining the electroporation efficiency by flow cytometry. Under our 
standard conditions, greater than 90% of cells were successfully electroporated with 
plasmids or siRNAs (Fig. 4.5B).  
After establishing conditions for DNA and RNA delivery, we attempted to 
manipulate gene expression in limb cells cultured in media containing FGF8 and 
purmorphamine. We first tested a Gapdh siRNA and quantified the level of mRNA 
knockdown at 24, 48, and 72 hours. Compared to cells electroporated with control siRNA, 
Gapdh was reduced 66% at 24 hours, 54% at 48 hours, and 56% at 72 hours at all time 
points (Fig. 4.5C). We then attempted to knockdown HoxD13 and Cdk6. We chose these 
genes because they are regulated by Shh signaling, and are expressed in the posterior distal 
limb (te Welscher et al., 2002; Panman et al., 2006; Lopez-Rios et al., 2012). Compared to 
cells electroporated with control siRNA, HoxD13 was reduced 64%, and Cdk6 was reduced 
80% (Figs. 4.5D,E). The expression of additional genes such as Tbp, Hoxa13, and Jag1 
were unchanged in HoxD13 and Cdk6 siRNA cultures (data not shown). We conclude that, 
in this system, both plasmids and siRNAs can be delivered in a highly efficient manner. 
Because the electroporation is performed in a 96-well format, this method can easily be 
scaled to accommodate higher-throughput assays.      
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After modulating gene expression levels, we sought to determine if this culture 
system could be used to assay the activity of DNA regulatory elements (promoters or 
enhancers). To test this, we utilized a well-established Hh responsive promoter for the 
Patched gene in Drosophila melanogaster.  This element has been used to measure Hh 
responsiveness in both Drosophila and mammalian cells when placed upstream of a firefly 
luciferase reporter gene (Nybakken et al., 2005; Yuen et al., 2006; Vokes et al., 2007). We 
modified this construct by placing the promoter element upstream of a codon-optimized 
Gaussia luciferase gene (dPtc-GLuc).  We used this reporter because it is more sensitive 
than firefly luciferase, and because it is secreted into the media, allowing the same sample 
to be assayed at multiple time points (Tannous et al., 2005). The dPtc-GLuc construct was 
electroporated into limb cells and half of the cells were cultured in control media (FGF8 
alone), and the other half were cultured in media containing FGF8 and purmorphamine. 
dPtc-GLuc stimulated a 6.9 fold increase in reporter activity in limb cells cultured in FGF8 
and purmorphamine media compared to cells cultured in control media (FGF8 alone) (Fig. 
4.5F). We conclude that this limb cell culture method can be used to test DNA regulatory 
element activity mediated by the Hh signaling pathway.  With minor adaptations, this 
system should be applicable to test the activity of DNA regulatory elements in a variety of 
different contexts.  
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Figure 4.5: Method to efficiently deliver plasmids and siRNAs into primary limb bud 
cells in culture.  (A) Illustration of delivering DNA/siRNA into cultured limb bud cells.  
E10.5 mouse forelimbs (red) are dissected, and limb cells are electroporated with plasmids 
or siRNA.  Limb cells are then plated on a 96-well half area plate, cultured, and assayed 
(qRT-PCR or Gaussia luciferase). (B) Flow cytometry histograms showing a 91.4% 
efficiency of electroporating plasmids (green) and 99.5% efficiency for siRNA (red) 
relative to the control (gray). (C-E) qRT-PCR showing gene expression in cultures 
electroporated with either a gene-specific siRNA or control siRNA. Gene expression is 
normalized to Gapdh in the control sample for each time point.  Limb bud cells 
electroporated with Gapdh siRNA show Gapdh knockdown at 24, 48, and 72 hours post-
electroporation (C). HoxD13 and Cdk6 siRNA knockdown shown at 24 post-
electroporation (D,E). Normalized Gaussia luciferase expression of a Hh responsive 
element (dPtch-GLuc) in media containing FGF8 only (control) or FGF8 and 
purmorphamine (PM) (F). Data points are the mean of 3 independent experiments and error 
bars represent the standard error of the mean. 
 
4.7: DISCUSSION 
 
This report provides methods for culturing relatively low numbers of mouse limb 
bud cells and electroporating plasmids and siRNAs. In an average experiment, we obtain 
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approximately 4.45 million forelimb cells per litter of mice, producing approximately 10 
wells of cells (from 5 electroporations). We routinely pool several litters, providing 
material for dozens of potential parameters in a single experiment. Therefore, this method 
should enable medium-throughput assays involving DNA regulatory elements and gene 
manipulation that were not previously feasible. Furthermore, the ability to manipulate Shh-
target genes suggests that it is possible to use this system to investigate Shh-mediated gene 
regulatory networks, and that this method could be adapted to investigate responses of 
other signaling networks present in the limb bud.  
 Despite these advances, there are a number of limitations to this in vitro system. In 
cultured limb cells, the multiple cross-regulatory interactions that occur between limb 
ectoderm and mesenchyme are no longer maintained. In their absence, there is a rapid 
downregulation of Shh activity (Honig, 1983; Anderson et al., 1993; Laufer et al., 1994; 
Niswander et al., 1994). By adding purmorphamine (Hh pathway activator) and FGF8, we 
short-circuit this loop but lose the information conferred by spatially and temporally 
regulated signaling. A second limitation is that many Shh-responsive genes could have 
inputs from additional signaling pathways that are not present in our culture conditions. 
For instance, WNT3a synergizes with FGF8 to maintain limb bud cells in a proliferative, 
undifferentiated state (ten Berge et al., 2008).  However, we did not add WNT3a to the 
culture media when assaying for Hh-responsiveness because we were concerned about 
potential cross-talk between the Hh and Wnt pathways. Ectodermally secreted WNTs are 
important for several facets of limb development (reviewed in (Rabinowitz and Vokes, 
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2012)), and in future experiments it would be interesting to determine their effects on this 
culture system.  
A caveat of using E10.5 limb buds in this culture system is that they have undergone 
some degree of specification. Previous work in chick has indicated that similar culture 
conditions are insufficient to reverse the specification of distal cells already committed to 
a distal fate (Cooper et al., 2011).  These results provide a possible explanation for the 
presence of the chondrogenic marker, Sox9, because it is already expressed in the limb bud 
when the tissue is harvested (Fig. 4.1E). However, the lack of further differentiation is 
indicated by the near absence of Alcian blue or Agc1 (Fig. 4.1C,D,F). In addition, many 
Shh target genes are only responsive to Shh during a transient time period (Panman et al., 
2006; Zhu et al., 2008). This provides a potential explanation for why we detect a modest 
induction of HoxD13 and Jag1, distal markers that remain Shh-responsive until at least 
E10.75 (Panman et al., 2006) but do not detect Hh-mediated upregulation of Grem1 and 
Hand2 (Fig 4.4).  
These caveats would likely be circumvented using limb bud cells obtained from 
earlier stage embryos or from Shh-/- embryos. Both of these are straightforward to 
implement, but would result in a large reduction in experimental material, limiting the 
utility for higher-throughput approaches. In future studies, we can imagine variations on 
this technique that utilize limb bud cells obtained from multiple genetic backgrounds. 
These methods could also be adapted to microfluidic-based approaches, allowing for 
reductions in required cell number while increasing the number of experimental 
parameters.  
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Chapter 5: Future directions and concluding remarks 
 
In this work, the previous chapters present evidence that GLI-target genes cluster 
into three distinct domains within the SHH responsive region in the developing mouse 
limb. In addition, GLI-target genes have distinct requirements for SHH signaling, and SP1 
acts as a factor to maintain gene expression for a cohort of GLI target genes (Chapter 2).  
Also shown, a GLI-bound CRM functions as a silencer in the anterior limb to robustly 
repress Grem1 (Chapter 3). And lastly, I demonstrate a medium-throughput platform to 
culture mouse limb bud cells in order to manipulate gene expression and test the activity 
of DNA regulatory elements (Chapter 4).  
 
5.1: MECHANISMS MEDIATING A TEMPORAL HEDGEHOG RESPONSE 
The data presented in Chapter 2 show that GLI target genes have different temporal 
requirements for SHH signaling. Interestingly, the expression pattern of GLI target genes 
correlate with the different temporal activities. Genes that require only an initial SHH 
signaling input are found in the central (category 2) and posterior-proximal (category 3) 
domains in the limb. Subsequently, we demonstrate that SP1 acts to maintain gene 
expression for a subset of GLI target genes. While this work begins to explore how GLI 
target genes are maintained, several outstanding questions remain: Does SP1 maintain GLI 
target genes in other HH regulated tissues? What molecular mechanisms are employed to 
maintain GLI target genes? Are there additional factors involved in mediating GLI target 
gene expression?   
HH signaling regulates the development of several embryonic tissues. Another 
well-established system used to study HH signaling is the developing neural tube. Since 
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Sp1 is expressed in essentially all cell types, albeit at variable levels, it would be interesting 
to determine if SP1 maintains the expression of GLI target genes in the neural tube (Saffer 
et al., 1991).  Interestingly, previous work identified a GC-rich Sp1 motif in neural GLI-
bound cis-regulatory modules (Vokes et al., 2007).  Further testing this hypothesis could 
be approached in vivo using a Sp1 conditional knockout allele; this approach could be 
applied to the mouse limb bud as well.  
The molecular mechanisms utilized to maintain transcription of GLI target genes 
are not well understood. Since Sp1 has been previously shown to mediate the interaction 
between distal regulatory elements with proximal promoters (Deshane et al., 2010; Su et 
al., 1991), it is worth investigating if such a mechanism is utilized to maintain the 
expression of GLI target genes.  As proposed in the model in Chapter 2, SP1 maintains 
chromatin interactions for a cohort of GLI-target genes. Further studies using 4C or Hi-C 
techniques to uncover the chromatin interactions around GLI target genes under wild-type, 
Shh-deficient, and Sp1-deficient conditions would clarify the functions for these factors.  
Lastly, much work in the neural tube has uncovered roles for several additional 
factors (SoxB1, Sox2, and Nkx2.2) that are involved in mediating a HH transcriptional 
response (Oosterveen et al., 2012; Oosterveen et al., 2013; Peterson et al., 2012; Lek et al., 
2010). It is interesting to speculate that there are additional factors involved in mediating a 
HH response in the developing limb. In this work (Chapter 2), DNA motif analysis for 
GLI-bound regions uncovered several novel sequences which do not correspond to a 
known transcription factor. Future studies using a DNA mutational approach are necessary 
to determine their contribution, if any, to regulate the activity of GLI-bound CRMs. 
Furthermore, determining the factors that bind to the novel DNA motifs would likely lead 
to the identification of domain specific co-factors for GLI-bound CRMs. 
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5.2: HOW DOES FGF INTEGRATE WITH SHH TO REGULATE GLI-TARGETS? 
The SHH-GREM1-FGF signaling loop is critical to drive limb outgrowth and 
patterning during development (Fig. 1.2) (Khokha et al., 2003; Litingtung et al.,  2002; 
Michos et al., 2004; te Welscher et al., 2002; Zuniga et al., 1999). The integration of the 
SHH and FGF signaling pathways to co-regulate a group of GLI-target genes is poorly 
understood. In this work (Chapter 2), the expression of a subset of GLI target genes was 
determined after inhibition of FGF signaling.  While the majority of GLI target genes were 
unchanged, interestingly, a group of GLI target genes were also downregulated or 
upregulated (Fig. 2.6).  The data indicate that a cohort of GLI target genes are reciprocally 
regulated by FGF signaling.   
Several genes including: Grem1, Osr2, Rasgef1b, Smoc1, Fam181b showed an 
increase in expression after FGF inhibition (Fig. 2.11). Interestingly, in wild-type limbs, 
these genes show expression patterns that are mostly restricted from the distal mesenchyme 
(Fig 2.2). Previous studies (and this work) demonstrate that inhibiting FGF signaling 
causes Grem1 to expand into the anterior-distal mesenchyme (Fig 3.6) (Verheyden and 
Sun, 2008). This raises the possibility that FGF signaling represses a larger cohort of GLI 
target genes from the distal mesenchyme. Further studies require determining how the gene 
expression domain changes after FGF inhibition.     
Moreover, the molecular mechanisms mediating distal repression of GLI-target 
genes are unknown. Evidence from this work demonstrate that FGF signaling does not 
repress Grem1 expression through the GLI-bound CRM, GRE1 (Fig. 3.6), suggesting that 
FGF mediates repression through distinct CRMs. Further studies to determine the CRMs 
which integrate FGF signaling to mediate repression of GLI target genes in the distal 
mesenchyme will highlight the integration of the SHH and FGF signaling pathways to 
sculpt gene expression domains.   
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5.3: DUAL FUNCTIONING GLI-BOUND CRMS  
Digit asymmetry in the developing limb is regulated by polarized gene expression. 
Recent work in the bovine limb demonstrates that the loss of polarized gene expression 
leads to a loss of digit asymmetry (Lopez-Rios et al., 2014). For mammals, including 
mouse and human, the asymmetric pentadactylous hand/foot is a key feature. As mentioned 
throughout this work, HH signaling drives asymmetric gene expression in the limb. In 
Chapter 3, the GLI-bound CRM, GRE1, was shown to robustly repress Grem1 in the 
anterior-distal limb.  In separate experiments using a mouse transgenic enhancer assay, 
GRE1 activated reporter expression, indicating that the element has enhancer activity. 
Taken together, GRE1 mainly functions as an anterior silencer element for Grem1, and 
GRE1’s role as a bonafide enhancer needs clarification.    
However, an outstanding question remains: Is it a general property of GLI-bound 
CRMs to function as dual silencers and enhancers?  Many GLI target genes are associated 
with multiple GLI-bound CRMs. How these CRMs individually or collectively regulate 
the expression of a particular GLI target gene is not known. Several GLI target genes 
including Hoxd13, Hoxd12, and Cdk6 have been shown to expand into the anterior limb 
(similar to Grem1) in Gli3-deficient limbs (Lopez-Rios et al., 2012). In this work (Chapter 
2), an in situ hybridization screen identified a cohort of GLI target genes that are 
predominately expressed in the Shh responsive region in the limb. It would be interesting 
to determine if the gene expression boundaries for this group of GLI target genes are 
changed in Gli3-deficient limbs. Furthermore, additional studies determining the ability of 
the associated GLI-bound CRMs to enhance and/or silence gene expression would be 
required.   
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5.4: CONCLUDING REMARKS 
The developing mouse limb bud is an excellent system to study a variety of 
biological processes including, signal transduction, transcriptional control, and cell 
dynamics. We are at the beginning stages of applying system-level experimental 
techniques in order to study these processes. Such approaches will provide much insight 
into how this multifaceted tissue grows and organizes during development.   
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Appendix A: GLI target gene expression patterns 
 
This appendix contains data pertaining to the spatial distribution of GLI target 
genes discussed in Chapter 2.   
 
A.1: SPATIAL DISTRIBUTION OF GLI TARGET GENES  
 
 
Figure A1: Schematized spatial distributions of GLI target genes in E10.5 mouse limb 
buds. Colored regions indicate areas where gene expression was observed. Multiple 
domains indicates at least 2 spatially unique expression domains; not detected indicates no 
expression detected and the asterisk indicates that expression was detected only later in 
E11.5 limbs for a subset of GLI target genes.  
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Gene name Distribution 
Cited4 AER 
Dlx5 AER 
Enpp1 AER 
Fzd7 AER 
Zic3 Anterior 
Epha3 Anterior 
Fam181b Central 
Ndnf Central 
Fam69c Central 
Cldn11 Central 
Cldn9 Central 
Fbxo41 Central 
Fbxo8 Central 
Hhip Central 
Osr2 Central 
Smoc1 Central 
Whrn Central 
Rspo3 Central  
Clstn2 Distal 
Arl6 Distal 
Baz2b Distal 
Mpnd Distal 
Hoxd10 Distal 
Igf1r Distal 
Lrrc20 Distal 
Zfp933 Distal 
Mnd1 Distal 
Mrpl23 Distal 
Olfr91 Distal 
Punc Distal 
Rgs19 Distal 
Rspo4 Distal 
Sall4 Distal 
Shcbp1 Distal 
Table A1: Classification of the spatial expression of GLI target genes in E10.5 mouse 
limb buds. Spatial categories indicated in the distribution column are schematized in Fig. 
A.1. Multiple domains indicates at least 2 spatially unique expression domains; not 
detected indicates no expression detected and the asterisk indicates that expression was 
detected only later in E11.5 limbs for a subset of GLI target genes.  
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Slc2a1 Distal 
Smad7 Distal 
Sp1 Distal 
Srp19 Distal 
Thap11 Distal 
Trim62 Distal 
Zfp64 Distal 
Trp53rk Distal 
Ppdpf Distal-periphery 
Aprt Distal-periphery 
Asf1a Distal-periphery 
Bmp4 Distal-periphery 
Fndc3c1 Distal-periphery 
Gpsn2 Distal-periphery 
Grcc10 Distal-periphery 
Id3 Distal-periphery 
Ier5 Distal-periphery 
Klf3 Distal-periphery 
Med30 Distal-periphery 
Arhgef3 Multi-domain 
Bmp2 Multi-domain 
Ebf3 Multi-domain 
Efna1 Multi-domain 
Kit Multi-domain 
Scube1 Multi-domain 
Sfrp2 Multi-domain 
Sulf1 Multi-domain 
Tbx2 Multi-domain 
Tbx3 Multi-domain 
Tmem30b Multi-domain 
Ust Multi-domain 
Wnt11 Multi-domain 
Hoxa7 Multi-domain 
Galp No probe 
Ppnr No probe 
Nrarp No probe 
Tas2r119 No probe 
Ube2v1 No probe 
Zfp353 No probe 
Table A1, cont. 
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Depdc7 Not detected embryo 
9830107B12Rik Not detected embryo 
Ap1s2 Not detected embryo 
Hccs Not detected embryo 
Jazf1 Not detected embryo 
Popdc3 Not detected embryo 
Prkce Not detected embryo 
Npvf Not detected embryo 
5430416O09Rik Not detected limb 
Apoa2 Not detected limb 
Dcn Not detected limb 
Isl1 Not detected limb 
Pqlc2 Not detected limb 
Drd3 Not detected limb 
Aldh1a2 Not detected limb* 
Ednrb Not detected limb* 
Eomes Not detected limb* 
Igfbp7 Not detected limb* 
Lum Not detected limb* 
Myl4 Not detected limb* 
Pdlim Not detected limb* 
A130014H13Rik Not detected limb* 
A530021J07Rik Not detected limb* 
Atp6v1g3 Not detected limb* 
Avpr2 Not detected limb* 
Pax9 Not detected limb* 
Gata5 Not detected limb* 
Gli1 Posterior 
Hand2 Posterior 
Ptch1 Posterior 
Ptch2 Posterior 
Dock6 Posterior-distal 
Calml4 Posterior-distal 
Cdk6 Posterior-distal 
Grem1 Posterior-distal 
Hoxd11 Posterior-distal 
Hoxd13 Posterior-distal 
Ier2 Posterior-distal 
Jag1 Posterior-distal 
Table A1, cont. 
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Klf9 Posterior-distal 
Msi2 Posterior-distal 
Pam Posterior-distal 
Ralgps2 Posterior-distal 
Rasgef1b Posterior-distal 
Sall1 Posterior-distal 
Sall3 Posterior-distal 
Sap30 Posterior-distal 
Shroom3 Posterior-distal 
Sox4 Posterior-distal 
Tpd52l1 Posterior-distal 
Runx3 Posterior-distal 
Adamts19 Posterior-proximal 
Cntfr Posterior-proximal 
Col23a1 Posterior-proximal 
Dlk1 Posterior-proximal 
Ltbp1 Posterior-proximal 
Lypd6 Posterior-proximal 
Osr1 Posterior-proximal 
Prdm1 Posterior-proximal 
Svep1 Posterior-proximal 
Pkdcc Proximal 
Bmpr1b Proximal 
Meis1 Proximal 
Meis2 Proximal 
Alx4 Proximal-anterior 
Hoxb4 Proximal-anterior 
Hoxc4 Proximal-anterior 
Irx3 Proximal-anterior 
Pax1 Proximal-anterior 
Pbx1 Proximal-anterior 
Ppp1r2 Uniform 
Cdc42ep4 Uniform 
Cobll1 Uniform 
Creb5 Uniform 
D16Ertd472e Uniform 
Efcab2 Uniform 
Haghl Uniform 
Hmga1 Uniform 
Kbtbd8 Uniform 
Table A1, cont. 
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Ncor2 Uniform 
Nfe2l3 Uniform 
Ppp2r4 Uniform 
Slc26a11 Uniform 
Slc35c1 Uniform 
Sparcl1 Uniform 
Tbx4 Uniform 
Tmem48 Uniform 
Trim59 Uniform 
Tct36 Uniform 
Tmtc1 Uniform 
Alg13 Uniform 
Zmiz1 Uniform 
Cyyr1 Weak 
Foxf1a Weak 
Foxf2 Weak 
Kcne3 Weak 
Tcte3 Weak 
2410187C16Rik Weak 
2610306H15Rik Weak 
3110043J09Rik Weak 
4921524J17Rik Weak 
4930525K10Rik Weak 
Cd302 Weak 
Cxxc4 Weak 
E130309F12Rik Weak 
Hook1 Weak 
Inha Weak 
Maml3 Weak 
Mgmt Weak 
Pmch Weak 
Polr2k Weak 
Prokr2 Weak 
Pus7l Weak 
Ramp2 Weak 
Sdk2 Weak 
Slc24a6 Weak 
Smo Weak 
Stxbp6 Weak 
Table A1, cont. 
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Tank Weak 
Thap1 Weak 
Tmem5 Weak 
Tmepai Weak 
Ube2t Weak 
Xpnpep2 Weak 
Zfp281 Weak 
Zfp704 Weak 
Tctex1d2 Weak 
Frmd8 Weak 
Trmt10c Weak 
Smug1 Weak 
Tpcn1 Weak 
Xpa Weak 
Table A1, cont. 
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A.2: GLI TARGET GENE EXPRESSION PATTERNS 
 
 
Figure A2: Category 1 (posterior and posterior distal) gene expression patterns in E10.5 
and E11.5 mouse forelimbs. 
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Figure A3: Category 2 (central) gene expression patterns in E10.5 and E11.5 mouse 
forelimbs.  
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Figure A4: Category 3 (posterior-proximal) gene expression patterns in E10.5 and 
E11.5 mouse forelimbs. 
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Figure A5: Multiple domain gene expression group in E10.5 and E11.5 mouse 
forelimbs 
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Appendix B: RNAseq 
 
 This appendix contains gene expression data generated from the RNAseq 
experiments discussed in Chapter 1.  The methods used to analyze this data can be found 
in Appendix C.   
 
 
B.1: DIFFERENTIALLY EXPRESSED GENES IN CYCLOPAMINE TREATED LIMBS 
 
Gene Symbol FC log2 PValue FDR 
Gli1 -3.1436 1.14E-35 2.00E-31 
Ptch2 -3.5246 1.86E-18 1.09E-14 
Fgf4 -4.2379 3.53E-14 1.24E-10 
Sall1 -1.2629 5.16E-14 1.51E-10 
Fgf8 -1.6897 7.48E-13 1.88E-09 
Mamdc2 -2.6636 1.19E-11 2.32E-08 
Ptch1 -1.4175 6.48E-11 1.14E-07 
Hoxd12 -1.3554 5.21E-10 8.32E-07 
Ina -8.1995 8.78E-10 1.29E-06 
A930011O12Rik -5.4016 9.10E-09 1.23E-05 
Elavl3 -2.7694 4.29E-08 4.73E-05 
Stmn2 -2.2772 4.31E-08 4.73E-05 
Tubb3 -1.909 4.26E-08 4.73E-05 
Myt1 -4.2316 5.08E-08 5.25E-05 
Thy1 -2.8683 8.10E-08 7.49E-05 
Ano1 -1.3849 7.96E-08 7.49E-05 
Hsd11b2 -1.1627 1.09E-07 9.11E-05 
Greb1 -0.9356 1.40E-07 0.00011 
Nhlh2 -3.2223 3.09E-07 0.00023 
Table B1: Cyclopamine RNAseq. Genes downregulated (≥25%, 0.1% FDR) in E10.25 
mouse forelimbs cultured in the presence of cyclopamine, a Hh pathway inhibitor. Log2 
expression is shown. Genes sorted by the false discovery rate (FDR).  
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Hoxd13 -1.0851 2.97E-07 0.00023 
Sall3 -0.947 3.27E-07 0.00023 
Rfx4 -4.5236 3.51E-07 0.00024 
Nhlh1 -5.1715 5.99E-07 0.00039 
Msi2 -0.8364 6.52E-07 0.00041 
Msx3 -4.3918 7.76E-07 0.00047 
Frem1 -0.9955 8.53E-07 0.0005 
Robo3 -4.4424 1.10E-06 0.00062 
Cntn2 -1.5186 1.90E-06 0.00104 
Aox3 -2.0027 2.04E-06 0.00105 
Mtus1 -1.1243 2.14E-06 0.00107 
Pou3f2 -3.1676 2.25E-06 0.0011 
Fabp7 -3.6102 2.47E-06 0.00117 
Neurod4 -7.0957 2.97E-06 0.00137 
Enpp2 -1.1723 3.78E-06 0.0017 
Grem1 -0.891 4.28E-06 0.00188 
Miat -1.8729 4.45E-06 0.00191 
Car12 -0.8459 6.17E-06 0.00252 
Slc17a6 -6.7562 1.19E-05 0.00426 
Scrt2 -4.1805 1.22E-05 0.00426 
Sox2 -3.3159 1.12E-05 0.00426 
Sost -1.5847 1.18E-05 0.00426 
Hoxd11 -0.9075 1.21E-05 0.00426 
Kdm5d -0.9009 1.19E-05 0.00426 
Chrna3 -3.7603 1.60E-05 0.00542 
Chl1 -2.1129 1.81E-05 0.00599 
Akap6 -2.013 1.87E-05 0.0061 
Slc1a2 -1.8176 2.22E-05 0.00697 
Srrm4 -2.6922 2.42E-05 0.00745 
Cdk6 -0.9908 2.86E-05 0.00837 
Tfap2c -0.8318 3.42E-05 0.00969 
Scg3 -4.6185 3.92E-05 0.01076 
Zic1 -3.4593 4.49E-05 0.01212 
Ccnd1 -0.7107 6.10E-05 0.01599 
Ppp2r2c -2.6222 6.22E-05 0.01608 
Pappa2 -1.4931 6.70E-05 0.01706 
Apcdd1 -0.6731 7.20E-05 0.01808 
Olig3 -6.5397 7.91E-05 0.01957 
Table B1, cont. 
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Dock6 -0.6647 0.00012 0.02918 
Lmo2 -0.8597 0.00015 0.03615 
Elavl4 -1.4405 0.00017 0.03893 
Gja8 -3.5064 0.00018 0.04081 
Zic4 -4.0419 0.00024 0.05122 
Neurog2 -6.5028 0.00027 0.05692 
Sst -3.5554 0.00029 0.06 
Cln6 -0.7028 0.00029 0.06 
Spry4 -0.62 0.00031 0.06432 
Wnt10b -1.9916 0.00037 0.07401 
Uty -0.8006 0.00038 0.07401 
Has2 -0.719 0.00042 0.08114 
Slc4a4 -0.7958 0.00044 0.08181 
Prtg -0.6674 0.00044 0.08181 
Lhx1 -2.839 0.00049 0.08947 
Pax6 -2.5219 0.0005 0.09009 
Gsx1 -6.1242 0.00054 0.09632 
Stac -2.6579 0.00057 0.09928 
 
Table B1, cont. 
 
 
 
 
 
 
 
 
 
 
 104 
B.2: DIFFERENTIALLY EXPRESSED GENES IN SHH-DEFICIENT LIMBS 
 
Gene name logFC PValue FDR 
Hoxd13 -6.009669587 2.52E-108 4.46E-104 
Hoxd12 -6.554686341 1.77E-104 1.57E-100 
Gli1 -5.714119311 5.46E-71 2.42E-67 
Hist1h2ab -2.522446436 1.32E-60 4.66E-57 
Fgf4 -6.905818531 1.11E-56 3.29E-53 
Hoxd11 -2.509735373 1.53E-52 3.86E-49 
Grem1 -2.626013966 5.69E-45 1.26E-41 
Ptch1 -2.367971302 5.43E-37 1.07E-33 
Ptch2 -4.409820957 6.34E-37 1.12E-33 
Frem1 -1.813423967 3.50E-35 5.64E-32 
Hand2 -2.155543855 3.16E-33 4.67E-30 
Sall1 -1.904572443 3.95E-30 5.38E-27 
Osr2 -4.00904607 5.02E-30 6.35E-27 
Mamdc2 -3.736843977 3.48E-28 4.11E-25 
Hoxa13 -4.641746714 1.97E-26 2.18E-23 
Ddx3y -1.471171848 2.59E-26 2.70E-23 
Eif2s3y -1.52010606 2.48E-23 2.44E-20 
AI506816 -1.725998004 3.81E-23 3.55E-20 
Rasgef1b -1.444915572 3.08E-19 2.48E-16 
Ccnd1 -1.180154143 1.30E-18 1.00E-15 
Aox3 -3.356518399 2.49E-18 1.76E-15 
Cbln1 -1.686346572 2.93E-18 2.00E-15 
Hey1 -1.317992716 4.73E-18 3.11E-15 
Kdm5d -1.375969559 1.53E-16 9.36E-14 
Sall3 -1.787394806 4.93E-16 2.91E-13 
Uty -1.497976371 1.41E-15 8.07E-13 
Hhip -2.995924586 2.71E-15 1.46E-12 
Cdk6 -1.612728183 2.82E-15 1.47E-12 
Scn11a -5.742201227 2.67E-14 1.28E-11 
Rspo3 -1.285191713 2.68E-14 1.28E-11 
Tpd52l1 -1.55839175 8.20E-14 3.63E-11 
Cpa2 -1.346326115 5.43E-13 2.29E-10 
5730457N03Rik -3.016163876 9.06E-13 3.70E-10 
Table B2: Genes downregulated  (≥25%, 0.1% FDR) in Shh-/- E10.25 mouse forelimbs. 
Log2 expression is shown. Gene expression sorted by false discovery rate (FDR).  
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Msi2 -0.947297051 1.05E-12 4.12E-10 
Pam -1.014214849 1.31E-12 5.04E-10 
Socs2 -1.105952356 1.39E-12 5.25E-10 
Nid1 -0.972989446 1.99E-12 7.33E-10 
1300002K09Rik -3.801442176 2.34E-12 8.47E-10 
Itga8 -1.168491418 5.24E-12 1.82E-09 
Mid1ip1 -1.542303715 1.01E-11 3.44E-09 
Hoxa11as -1.118485568 1.44E-11 4.72E-09 
Cyp26b1 -0.952961447 1.57E-11 5.06E-09 
Gpt2 -0.888039192 2.45E-11 7.76E-09 
Cyp1b1 -1.347183489 3.23E-11 9.69E-09 
Sgms2 -2.052733554 5.40E-11 1.57E-08 
Shh -1.790774934 6.58E-11 1.88E-08 
Gbx2 -2.118878938 1.16E-10 3.22E-08 
Ppp2r2c -2.985081511 1.36E-10 3.70E-08 
Hoxd10 -0.904859269 1.58E-10 4.23E-08 
Eogt -0.897337773 1.66E-10 4.39E-08 
Rnd3 -0.835057295 2.11E-10 5.42E-08 
Cpm -1.003094513 2.40E-10 5.98E-08 
Gpx2 -2.624989208 3.29E-10 8.03E-08 
Enpp2 -1.163546063 4.27E-10 1.02E-07 
Bcat1 -0.851042728 5.37E-10 1.27E-07 
Frzb -0.810370728 1.16E-09 2.63E-07 
Fgf8 -1.731682449 1.55E-09 3.43E-07 
Ntm -2.280540742 2.24E-09 4.83E-07 
Hsd11b2 -1.242478795 3.34E-09 7.05E-07 
Smoc1 -1.432903526 4.59E-09 9.46E-07 
Emb -0.791508169 5.25E-09 1.07E-06 
Cmah -0.917201795 6.48E-09 1.30E-06 
Wnt5a -0.743973753 1.34E-08 2.55E-06 
Pou4f1 -3.21530322 1.59E-08 2.99E-06 
Fgf9 -1.85862692 2.75E-08 4.87E-06 
Naaa -1.278812552 3.08E-08 5.30E-06 
Calml4 -2.224692749 3.69E-08 6.23E-06 
Adamtsl2 -1.675004396 5.29E-08 8.39E-06 
Spry4 -0.951162092 5.30E-08 8.39E-06 
Sall4 -1.17052878 8.36E-08 1.28E-05 
Osr1 -1.390562319 1.09E-07 1.60E-05 
Table B2, cont. 
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Fgf10 -0.931807163 1.15E-07 1.69E-05 
Dusp4 -0.778148895 1.68E-07 2.39E-05 
Has2 -0.816115205 1.97E-07 2.70E-05 
Gldc -0.987696501 2.18E-07 2.93E-05 
Jag1 -0.860090694 2.81E-07 3.68E-05 
Kbtbd8 -0.779968648 4.01E-07 5.11E-05 
Tmem173 -0.859456044 4.21E-07 5.33E-05 
Prdm1 -1.147649933 4.29E-07 5.39E-05 
D7Ertd715e -0.898788472 4.63E-07 5.73E-05 
Pdlim3 -2.370038864 4.78E-07 5.88E-05 
Gucy2c -3.13947821 5.08E-07 6.21E-05 
Mtus1 -0.918797186 5.46E-07 6.58E-05 
Evx1 -2.452171405 5.81E-07 6.96E-05 
Fst -1.744048492 6.68E-07 7.84E-05 
Shisa2 -0.984808516 7.43E-07 8.54E-05 
Gcnt4 -1.936118071 8.66E-07 9.90E-05 
Mthfd2 -0.686460798 9.48E-07 0.000106916 
Olfm1 -0.723972274 1.25E-06 0.000136226 
Dkk4 -4.6027019 1.59E-06 0.000169152 
Cxxc4 -1.106765871 1.73E-06 0.000182901 
Lmo2 -0.92726587 1.77E-06 0.00018599 
Chl1 -1.323889863 1.87E-06 0.000192371 
Slc1a4 -0.749582312 2.02E-06 0.000207 
Megf10 -1.853046266 2.04E-06 0.00020731 
Evx2 -7.150867391 2.39E-06 0.000241658 
Serinc5 -0.741506458 2.67E-06 0.000264634 
Pmaip1 -0.623152515 2.74E-06 0.000270038 
Lmo1 -0.816799218 3.37E-06 0.00032092 
C1galt1 -0.685904459 3.57E-06 0.000338131 
Arid3a -0.67980241 3.59E-06 0.000338458 
Sost -1.042115707 3.96E-06 0.000368009 
Hoxa10 -0.625854558 3.98E-06 0.000368009 
Map1b -0.748357994 4.43E-06 0.000402801 
Lypd6 -1.266670047 5.10E-06 0.00044728 
Lin28b -0.686086908 5.48E-06 0.000475927 
Tubb6 -0.761249881 5.96E-06 0.000506487 
Cirh1a -0.590270957 6.56E-06 0.000553117 
Bcl2 -0.802325613 6.59E-06 0.000553221 
Table B2, cont. 
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Cd24a -0.625899016 6.71E-06 0.000560408 
Scd1 -0.57749676 1.02E-05 0.000809596 
Slc8a3 -1.344553435 1.07E-05 0.000838903 
Phlda1 -1.238688622 1.08E-05 0.00084851 
Chrna1 -1.298865837 1.20E-05 0.00092947 
Kcne3 -0.942221043 1.22E-05 0.00093485 
Taf4b -0.752382738 1.30E-05 0.000985419 
Chrdl1 -0.802811101 1.33E-05 0.001003821 
Rcsd1 -0.880169045 1.55E-05 0.001143453 
Slc1a5 -0.655696176 1.54E-05 0.001143453 
Fam46a -1.233790281 1.88E-05 0.001358131 
Rragd -0.595782288 2.08E-05 0.001472679 
Gad1 -2.992703067 2.40E-05 0.00165534 
Gnai1 -0.658257815 2.41E-05 0.001656504 
Hprt -0.557934392 3.17E-05 0.002125197 
Gnb4 -0.696119345 3.38E-05 0.002247442 
Shisa3 -1.140989621 3.64E-05 0.002395829 
Trim71 -0.674894981 3.85E-05 0.002526494 
Syndig1 -1.951813826 4.06E-05 0.002632976 
Rprml -3.988427265 4.10E-05 0.002653198 
Nlrp1a -0.809881116 4.18E-05 0.002692624 
Tagln2 -0.622920319 5.22E-05 0.003278901 
Rab34 -0.59094049 5.27E-05 0.003297158 
Slc35d3 -1.706511645 6.01E-05 0.003719237 
Srms -1.626142155 6.30E-05 0.003871492 
Calm1 -0.568741463 6.37E-05 0.00388916 
Fbxo8 -0.684093415 6.54E-05 0.003967622 
Nrp2 -0.512300244 6.59E-05 0.00398594 
Gpd1l -0.591423816 6.73E-05 0.00404333 
Ets2 -0.527706077 6.93E-05 0.004119801 
Vwde -1.123167311 7.27E-05 0.004276961 
Sv2b -2.277281716 8.69E-05 0.004859928 
Atp1a2 -1.234979022 8.75E-05 0.004859928 
Krt23 -2.114121661 9.35E-05 0.005124856 
Mir17hg -0.502319928 9.32E-05 0.005124856 
Alg13 -0.589952744 9.51E-05 0.005188183 
Fdps -0.516132208 0.000101431 0.005477264 
Mycn -0.666281579 0.000110351 0.0058695 
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Fam19a4 -2.283954704 0.000115718 0.006079054 
Timm23 -0.547997657 0.000119462 0.00620501 
Prdx6 -0.48649853 0.000119125 0.00620501 
Padi3 -0.977858633 0.000121517 0.006274264 
Irs1 -0.577999103 0.000121858 0.006274264 
Galnt11 -0.54667955 0.000127502 0.006508124 
Acsl4 -0.56455966 0.000137118 0.006958829 
Rgag1 -2.561093987 0.000147703 0.007321847 
Eda2r -1.043021118 0.000161221 0.007886451 
Cdc6 -0.488957959 0.000163623 0.007961801 
Hs3st6 -1.892636241 0.000167334 0.008072866 
Lbh -0.498016106 0.000167971 0.008072866 
Dusp6 -0.481423932 0.000172756 0.00826986 
Rasl11a -0.674872162 0.000188063 0.008930202 
Larp4 -0.494060794 0.000187863 0.008930202 
Cxcl12 -0.579187695 0.000191837 0.009085076 
Ddx39 -0.473808082 0.000203044 0.009564647 
Mfsd2a -0.707926058 0.000210512 0.009863982 
Tmem256 -0.699658621 0.000214984 0.009968031 
Vcan -0.499029708 0.000223718 0.010290244 
Nop2 -0.473140404 0.000228933 0.010450666 
Gja3 -0.986530151 0.000232246 0.010574655 
Rbm20 -1.271339359 0.000244245 0.011065397 
Ctps -0.472975647 0.000248862 0.011215871 
Esm1 -1.00359957 0.000250078 0.011242085 
Heatr1 -0.488002295 0.000254202 0.0113856 
Itm2a -0.469152123 0.000263475 0.011666655 
Sc4mol -0.535578084 0.000269397 0.011899146 
Sdad1 -0.518043637 0.000278058 0.012190484 
Fam64a -0.642172209 0.00028394 0.012326326 
Dusp9 -0.488070508 0.000283795 0.012326326 
Itgav -0.472228843 0.00028383 0.012326326 
Hoxa11 -0.700269146 0.000291642 0.012598952 
Hgf -0.538773484 0.000293937 0.012667174 
Cited1 -1.164737383 0.000298448 0.012799098 
Abcc4 -0.92034169 0.000299166 0.012799098 
Cnr1 -0.742910238 0.000307804 0.013105341 
Sel1l3 -0.945135823 0.000322742 0.013578164 
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Atp10d -0.554395585 0.000365982 0.015075044 
Gcat -0.568564352 0.000378713 0.015527246 
Dmrta1 -1.382612379 0.000385598 0.015773012 
Ttn -0.887027783 0.000392748 0.015883046 
Hus1 -0.461410429 0.000391623 0.015883046 
6030408B16Rik -1.119576697 0.000400318 0.016145292 
Hist1h3h -0.713220512 0.00041708 0.016649876 
Rpf2 -0.484962252 0.000417375 0.016649876 
Tgm3 -2.10482046 0.000429102 0.016852005 
Greb1 -0.598670964 0.000441152 0.017172948 
T -1.829507614 0.000446138 0.017328942 
Otud4 -0.453523716 0.000453084 0.017407849 
Edar -0.775071378 0.000458027 0.017528292 
Apln -0.785434811 0.000472629 0.017982622 
Col19a1 -1.278599372 0.000501282 0.018810804 
Lama1 -0.518378013 0.000500824 0.018810804 
Krt17 -1.27229783 0.000502463 0.018815258 
Ccne1 -0.466893294 0.000507336 0.018917761 
Hist1h2ag -0.909862301 0.000516397 0.019110293 
Lgalsl -0.563555511 0.000521704 0.019227483 
Ddx21 -0.464807776 0.000524327 0.019227483 
Naf1 -0.63449942 0.000550961 0.020038224 
Slc25a15 -0.514504009 0.000584293 0.021077388 
Asns -0.487096182 0.000597151 0.021453836 
D16Ertd472e -0.518056782 0.000603927 0.021566038 
Mthfd1l -0.496958233 0.000603166 0.021566038 
Mthfd1 -0.457432829 0.000626285 0.022229968 
Uroc1 -2.843087171 0.000665265 0.023300226 
Pitrm1 -0.451410616 0.000666961 0.023300226 
Nsmaf -0.449564493 0.000673856 0.023448588 
Prss12 -0.813978447 0.000679554 0.023529129 
Sms -0.435748316 0.000680156 0.023529129 
Ppat -0.452925956 0.000685728 0.023675671 
Prss50 -2.433845106 0.000693845 0.023909307 
Psat1 -0.473983579 0.00069846 0.024021608 
Aimp2 -0.530540393 0.000704027 0.024166121 
Pvt1 -0.80212056 0.000719171 0.024628091 
Abce1 -0.477785812 0.000720266 0.024628091 
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Cdk2ap1 -0.436609305 0.000725552 0.024761019 
Polr1b -0.454739707 0.000727678 0.024785834 
Bhlha9 -0.740781135 0.000755278 0.025446434 
Shmt1 -0.449163998 0.000752982 0.025446434 
Zfp280c -0.447474603 0.000761397 0.025541408 
Nhp2 -0.524563465 0.00076825 0.025722589 
Dhcr24 -0.475866043 0.000776327 0.025934798 
Pdzd2 -0.84947475 0.000831249 0.027481521 
Dleu7 -5.781440428 0.000851989 0.027997087 
Prkg2 -1.098773242 0.000860304 0.028062838 
Dctpp1 -0.535208265 0.000861912 0.028062838 
Foxd2 -2.148944337 0.000868727 0.028204665 
Tfap2c -0.588590703 0.000879513 0.028204665 
Arid3b -0.510488492 0.000878588 0.028204665 
Ifrd1 -0.470317273 0.000877924 0.028204665 
Fam60a -0.452189062 0.000882192 0.028204665 
Saa2 -3.239346694 0.000891591 0.028453799 
Nolc1 -0.436447594 0.000893264 0.028455919 
Insig1 -0.448413565 0.000924511 0.029136901 
Slc7a6 -0.425431306 0.000953997 0.029853701 
Cntfr -0.79963146 0.00099514 0.030977027 
Ppp6c -0.443234178 0.001021541 0.03168744 
Plcg2 -0.788930156 0.00104449 0.032118065 
Mif -0.449104377 0.001053285 0.032276452 
8430423G03Rik -3.690091251 0.001071025 0.032760177 
Man2a1 -0.480470247 0.001075368 0.032760177 
Aprt -0.426320586 0.001076469 0.032760177 
Npm3-ps1 -1.69729813 0.001080649 0.03283098 
Gm5127 -1.559048951 0.001082938 0.032844178 
Slc25a5 -0.531334719 0.001106769 0.033225592 
Cck -5.775406112 0.001125706 0.033566513 
Gas5 -0.420033368 0.001150671 0.033986277 
Mat2a -0.432102783 0.001157516 0.034056345 
Ddx18 -0.431943577 0.001179532 0.034532027 
N4bp3 -0.609363387 0.001185084 0.034580244 
Rrp12 -0.451951484 0.001220714 0.035228459 
Snhg5 -0.440929994 0.001221221 0.035228459 
Aen -0.497835672 0.001229179 0.035400341 
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Polr1e -0.472644258 0.001266411 0.036004297 
Clhc1 -0.721209108 0.001324112 0.037290827 
Hes1 -0.439783798 0.001339429 0.037597414 
Mical2 -1.291151148 0.001361055 0.038058394 
Tagap1 -0.517996634 0.001362298 0.038058394 
Cpne5 -1.214374473 0.001380447 0.038444139 
Mycl1 -0.466820303 0.001403697 0.038726283 
Naa25 -0.420543655 0.00143587 0.03930778 
Nmd3 -0.456529414 0.001473248 0.040144872 
Hccs -0.475402088 0.001505701 0.040840701 
Tkt -0.429831669 0.001515169 0.041034682 
Rtn4rl1 -2.331254283 0.001532827 0.041386319 
Galk1 -0.429430331 0.001543113 0.041600622 
Tbrg4 -0.474525449 0.001552456 0.041788908 
Ydjc -0.974584329 0.001570396 0.042143728 
Dnmt3b -0.432011938 0.001607018 0.042866724 
1700001O22Rik -1.383906148 0.001645593 0.043437789 
Zfp275 -0.429627583 0.001648046 0.043437789 
Tuba1c -0.419003051 0.001646413 0.043437789 
Smyd2 -0.48092095 0.001671988 0.044003344 
Rsl1d1 -0.476731065 0.001697421 0.044540328 
Exosc9 -0.414572526 0.001741067 0.045416462 
Tmem215 -5.74214984 0.00175654 0.045618541 
Ldlr -0.426870439 0.001756199 0.045618541 
Cse1l -0.454902893 0.001759348 0.045624544 
Phf16 -0.455924935 0.001768813 0.0456694 
Wdr18 -0.422401306 0.001805706 0.046249859 
Rnf125 -0.747080628 0.001811351 0.046295301 
Lrrtm4 -1.206453138 0.001851683 0.047125144 
Rbpms2 -0.634380927 0.001854462 0.047125144 
2310061I04Rik -0.740372385 0.001903675 0.048031177 
Zfp9 -0.503664374 0.001916404 0.048283567 
5830417I10Rik -0.482706779 0.001926998 0.04848153 
Gnl3 -0.455290441 0.001943954 0.048769559 
Tle4 -0.4284246 0.001977683 0.049336216 
Nap1l5 -0.963340222 0.002113883 0.05178576 
Fat3 -0.456850102 0.002121115 0.051891155 
Fstl5 -2.294954733 0.002125481 0.051926229 
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Usp14 -0.418626548 0.002131568 0.052003222 
Thbs1 -0.440280643 0.002149132 0.052286325 
Eef1e1 -0.47358928 0.002239476 0.053966809 
Tmc7 -0.626172455 0.002290632 0.05504977 
Klf9 -1.025909613 0.00233232 0.055824394 
Ptpmt1 -0.502692201 0.00233598 0.055836549 
Ipo11 -0.429131615 0.002384273 0.056533127 
Dock6 -0.491159627 0.002427961 0.057492046 
Slc25a33 -0.58766669 0.00247459 0.058129898 
Akr1c19 -1.777488984 0.002492666 0.058262071 
Slc14a2 -2.126337298 0.002514992 0.058535521 
Pknox2 -1.032693774 0.002561955 0.059255055 
Slco4a1 -1.664291252 0.002568217 0.059298346 
Pus7 -0.426346983 0.002638778 0.060698756 
Nme1 -0.425773284 0.002672066 0.061146807 
Dars -0.426980901 0.002681619 0.061286237 
Pear1 -0.581442316 0.002744452 0.062320173 
Bche -0.612526536 0.00276711 0.062754235 
Lrig1 -0.459735521 0.002840325 0.063923559 
Zfp961 -0.426368319 0.00287511 0.064542383 
E2f5 -0.510974996 0.002902843 0.065082477 
Jazf1 -0.800963135 0.00292374 0.065385462 
Zfp948 -0.46403483 0.002977493 0.066402108 
Tma16 -0.448422541 0.002983609 0.066402108 
Plscr1 -0.436362662 0.002988566 0.06641592 
Sf3b4 -0.453845802 0.003021627 0.066898816 
Pde3b -0.422904441 0.003036777 0.067066585 
Nsdhl -0.52054298 0.003074128 0.067387331 
Xpo4 -0.465833857 0.003088285 0.067613978 
Cdr2 -0.439292737 0.003174266 0.06889706 
Gm3086 -1.747414069 0.003235885 0.069809972 
D19Bwg1357e -0.411027768 0.003268275 0.070422986 
Timm8a1 -0.486430934 0.00328497 0.070525325 
Pgf -0.743315132 0.00334414 0.070935816 
Rangrf -0.437021479 0.003348517 0.070943704 
Calcrl -0.464390382 0.003448486 0.072428559 
Etv4 -0.435165865 0.003531112 0.073580074 
2310069G16Rik -2.961188768 0.003576594 0.073919051 
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Cdc42ep3 -0.653376922 0.003588983 0.074088659 
Litaf -0.438546965 0.003649674 0.075113439 
Thy1 -5.591871524 0.003703956 0.075755732 
Creg2 -2.296767733 0.003734941 0.076125756 
Pycr2 -0.433809349 0.003746208 0.076267625 
Maff -0.780358304 0.003896216 0.0784202 
Mars2 -0.545258407 0.003924277 0.078716648 
Chchd4 -0.458997895 0.003939317 0.078858833 
Kctd1 -0.451579716 0.003968371 0.078858833 
Leprotl1 -0.433340412 0.00398784 0.0790074 
Haus2 -0.422937624 0.004073148 0.080517415 
Cdh19 -5.349440061 0.004347769 0.08416141 
Dppa4 -5.349437968 0.004343636 0.08416141 
Fcrl6 -5.349436145 0.00434004 0.08416141 
Acat3 -1.06397713 0.004389923 0.084884621 
Ppa1 -0.412412039 0.004458063 0.0859208 
Hist4h4 -0.455470379 0.004463183 0.085925967 
Gm21057 -5.599481858 0.004501228 0.086470454 
Slc6a2 -5.456366843 0.004603105 0.087623081 
Saa1 -5.370059736 0.004612308 0.087623081 
Siglecg -5.370046797 0.004609588 0.087623081 
Gar1 -0.617503795 0.004630019 0.087623081 
Snord35a -1.349074372 0.004709493 0.087903195 
Mir20a -0.835471977 0.004687954 0.087903195 
Arhgap9 -0.710624113 0.004709809 0.087903195 
Hk2 -0.461828149 0.004744513 0.08827187 
Pla2g12a -0.484262385 0.004784374 0.08864104 
Pgbd5 -0.93301453 0.004802712 0.088702431 
Slc41a1 -0.447124251 0.004792953 0.088702431 
Usp9y -3.725807611 0.004885925 0.090051505 
Ndufaf4 -0.476016987 0.00493185 0.090803454 
Sema5b -1.552956892 0.004964244 0.090964926 
Cth -0.410976376 0.005020121 0.091477755 
Tcfl5 -0.890647148 0.005203563 0.093785338 
Tfrc -0.518363325 0.005333813 0.095042761 
Svep1 -0.631830061 0.005342614 0.095103902 
Hesx1 -1.607223291 0.005366467 0.095241341 
Plaur -1.725144745 0.005490781 0.096685827 
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Dclre1b -0.462318762 0.005491528 0.096685827 
Gfra3 -1.181803164 0.005587637 0.097891424 
Ablim2 -1.816307587 0.00572804 0.099389682 
Fam199x -0.410845221 0.00573817 0.099446644 
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Appendix C 
 
C.1: MICE AND ETHICS STATEMENT 
Experiments involving mice were approved by the Institutional Animal Care and 
Use Committee at the University of Texas at Austin. E10.5 embryos (33-36 somites) were 
obtained from Swiss Webster crosses.   
 
C.2: WHOLE-MOUNT IN SITU HYBRIDIZATION 
Whole-mount in situ hybridization was performed on a minimum of two Swiss-
Webster embryos per stage at E10.5 and E11.5. Antisense probes were generated from 
plasmids as described previously (Yu et al., 2012).  in situ hybridization was performed on 
an in situ hybridization robot (Intavis) as described previously (Yu et al., 2012). 
 
C.3: RIBOPROBES  
 
Gene name Forward primer Reverse primer RIKEN ID 
0610012D17Rik ccgaccacacttccttcta tgaattttcccctttttctc 0610012D17 
1200004M23Rik caagttcagtgtttgccttc gtgaggtcagccttttcttt E430022B16 
1600014K23Rik ccacagccacactctacttc agagcaggaagggaataatg 2510019J21 
Table C1: Generating riboprobes against GLI target genes. DNA template used to 
generate a riboprobes are from the RIKEN Fantom2 collection. Forward and reverse 
primers used to amplify regions are indicated. Riboprobes generated by other methods 
such as linearization of plasmid, generated from other non-RIKEN plasmids, or mouse 
limb cDNA are indicated.   
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2410187C16Rik ctgttgtcctctcctcctg gtgtcttccctggtagctct 2410187C16 
2610306H15Rik tttgtcaacttctggaatgg tctggacagtaggctcaaaa 2610306H15 
2700038C09Rik gggtcctaaagtggtgtttc tcaggaaagttcagtgctgt 2700038C09 
2810408P10Rik Linearized plasmid Linearized plasmid 2810408P10 
3110043J09Rik cagtcacaagtttgggaaaa ccagatcaagttcaatccaa E030002L15 
4921524J17Rik cttcaaactctgttggttgc tgatacagcctcaaatgctt 4921524J17 
4930525K10Rik Linearized plasmid Linearized plasmid 4930525K10 
5430416O09Rik ctggactgttgtgtgaggtt gaaacaccttgtgctctctg 5430416O09 
9430076C15Rik cattcagaagccaaaatgag ctttctgcatggctgttatc D430026C09 
9830107B12Rik gaggatccacaggaccttac tcagctcctcctttgacata 9830107B12 
A130014H13Rik taccgttatgatgtgcttcc agaacaagcacgcagaaata A130014H13 
A530021J07Rik aagcgtagacatctggttca ttctggctggagacataaaa A530021J07 
A830059I20Rik ctgctcttttcgactctctg gcgctgtaatcataggacac A830059I20 
A930038C07Rik gctgttctactggtgtttgc gcattcatctttgtttctgc 4831422J22 
Adamts19 agaagaatctttgccaggac tcaccaacaggatcaaagtc D030062M24 
Aldh1a2 cacaggctctactgaggttg cgcatttaaggcattgtaac 6820449I02 
Alg13 aggaagctgtttggagagtc aatgctgatttttctcacca E430039H24 
Alx4 ggggattcccaggaggcgac gcaaggagacatacctgggcg limb cDNA 
Ap1s2 ctaccctcgcagcctaag gaggcagtgaccatctacag B230210K03 
Apoa2 aaggactgcagcacagaat  gtttaactccttccgcattt I530003A11 
Aprt tcgactacatcgcaggtcta caaaacggtttattgatctcc 0610008N13 
Arhgef3 agaccttcgatgtgtgtgtc ggaaaacatggagtttcaca 1200004I24 
Arl6 cagactttcaggtttgcttg aaaacgttcttccagagtcc 1110018H24 
Asf1a gaaaacccaccagtaaaacc aaaccctggtggcatataat E430021K15 
Atp6v1g3 gaggcaagctaaggaagaag ttaggcagggataactgtga 6720467K22 
Avpr2 ggaaccaagaaataggcagt acgttgagcaaagatgaaga D630034C19 
AW548124 ctacacttgttccgaagtgg gagcactctgagactggttg 5730519I16 
B230399E16Rik gttctcctcaacacacagga cacacaatcccatgcttatt B230399E16 
Baz2b acgatctggaagaggaagag tcttgaatgacgctttgaat 5830435C13 
Bmp2 Linearized plasmid  Linearized plasmid Lab plasmid 
Bmp4 Linearized plasmid  Linearized plasmid Lab plasmid 
Bmpr1b tctttagcactcaaggcaag atgatgaatccgtgtttctg D930007I02 
C330023D02Rik cagaggactgggtcattgta atcacagccagggaatatct A530078P09 
Calml4 gagaaccaaactcagttcca gcagtggttgtgtcatctct 2010002G05 
Cd302 cctgctaggcatgttctatg gttagatccaggatggttcc 0610038N09 
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Cdc42ep4 gagggctgtgtaggaaaagt ggtgtgtgtgtgttgtgtgt 1500041M20 
Cdk6 atcacccgtacttccaagat tccattgtgaatcacctttc 9130423C03 
Cited4 ggctgtctgtttcttttgc tctgagaagcaatcgaactc 2610524B15 
Cldn11 actggtctctaccactgcaa aatcaacaacaatggaatgc 1500001D22 
Cldn9 ccgcagctgtgaggtctggc cgcggggacgctcaaagtgt Limb cDNA 
Clstn2 gtcctgtagccctcacttct ccttgaagagtgcctgtatg C130053D20 
Cntfr cccgcagccgactagttag tattttattaacaacttaa 4930502A07 
Cobll1 gactttgagctcaccaactg tgatgttccctgactaccag D430044D16 
Col23a1 tcaaaattcaggtgtggttc tgtgagcctcagatttccta 6820412L02 
Cxxc4 aggcccactcacaaagtagt gttttgtacatgccccataa A830026K07 
Cyyr1 accggtctctgtcctaaaga tctccacctatctctgagca 6330416N05 
D16Ertd472e tcagtgagaggccataaaga tagaggatgaaagcaggaca A930031E11 
Dcn tgggctgcatagttagtgtt caccctcacctcatagtgaa 9530076L14 
Depdc7 gatagcagttgcagccttta cgtctaaactcctccctgtt 6330584N14 
Dlk1 gtgtcaatggagtctgcaag ctccttgttgaaagtggtca 1600023D19 
Dlx5 tggaggacttttgaagaggt gcagccttattaatgtgtcg F930032M16 
Drd3 ggtgagcctggctgtggcag tggccaggagagaggggctg Limb cDNA 
E130307M08Rik aggaggaggaagaagatgtg tatcttggacatacgccatc 2610511M14 
E130309F12Rik ccgtggtggttaattgtaaa ctgagaagcacagacactcc E130309F12 
Ebf3 tctgatgccttaaaagtgga aatcgaggcaatttagttcc 3110018A08 
Ednrb gacagatatcgagctgttgc agttgtcatatccgtgatcg D030003K13 
Efcab2 agcagaatatggagggagag tcttttgtgcaaccttcagt 4931421D06 
Efna1 gtgactgtcaatggcaaaat gaaatcttgcagagatgctg 2310004J15 
Enpp1 tgggtcagtaccatttgaag gggatcaaacccagtaagtc E430029D02 
Eomes acaatgttttcgtggaagtg cgatgtctagcttgttggtc F830028H02 
Epha3 aaacacagtgcagaggagaa caatcccgtaactccataca B130048J04 
Fbxo41 gctgtcagtgctggatactc gaaaccacaacttggagaca 9630017H13 
Fbxo8 agaacttggccttagtcctg ggtcagatccaactttgaca 6330500C02 
Foxf1 tcagcaagtgaaaagggata tccctcatctcagtgtgttc E030047N19 
Foxf2 gcatgtcttcctactcgttg gctttcttgaaattgtgtgc 4022445M22 
Fzd7 ctgctagagtcctagcgtga caggtggatgtctgtgagtt 2310081G03 
Gata5 cagtcatctactggctggag gaatttcaactcccaacaca 9130423G08 
Gli1 Linearized plasmid Linearized plasmid Lab plasmid 
Gm784 gagagatcccagatgtttcc aattcaggttgttgggagat D130058O17 
Grcc10 ctctcttcccaaggacagtt gcacacatacgagaaccaat 3010025G03 
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Grem1 Linearized plasmid Linearized plasmid Lab plasmid 
HaghI gaccatgaaggtcaaagtca  tcgaaggcacagtaggaata B930082I15 
Hand2 Linearized plasmid Linearized plasmid Lab plasmid 
Hccs tccattgcagatgataggtc aaccagttttcaacagcaaa 5730448P21 
Hhip acctagcacttccactcctc ccaatgtgatcataccatcc 6330416O15 
Hmga1 gacaaggctaacttcccatt caaattcaggaggatgaaca 2410030H14 
Hook1 atgaccctggaagaatctgt gccttcttcagctcttcttc A830044F05 
Hoxa7 gaaggaattccatttcaacc atcatggtttgcaggtattg 9030406A02 
Hoxb4 acagcctggatttttctttc accaacaaaaggttctaggc 5730551B08 
Hoxc4 ttacgtcttcgcaaatgaat agctagcgaccctgtaaagt D030011O04 
Hoxd10 aattacaccgggaatgtttt ctctccacttgggagacttt 6030426C21 
Hoxd11 taatttccctcccaacattt cctcttggcaaataaggttt E230017H14 
Hoxd13 Linearized plasmid Linearized plasmid Lab plasmid 
Id3 tgtctcttttcctccctctc attctcggaaaagccagtc 0610039A06 
Ier5 caaacctcatcagcatcttc ccagacgaactccctctagt I830008A05 
Igf1r aattgtggttcaccctcttt acacccacaagaaactgaaa A330103N21 
Igfbp7 ttctgttcctctcctcttcc gtggcactcatactctccag 0610007D03 
Inha ctcccaggctatccttttcc gaaactgggagggtgtacga Limb cDNA 
Irx3 ggagatcgatttggaaaact caaggcactacagcgatatt E030042N12 
Isl1 ttctgaatggtgctgtttct tctacatatggcgctttgat G630030I18 
Jag1 ggcagccttaggatcatagt agcaggaaagaaagaggaaa 6230411J17 
Jazf1 cagcgagtatgatgaggaag tgtgagtcgatgtgttgaaa C820002C15 
Kbtbd8 tccatgcttgcagtattctt gcaaactgaggaggaatttt D230024C02 
Kcne3 accagtgtttctgtctgtgc atatgtgttcatgggctctg 2210017H05 
Kit cttgattaagtcggatgctg ggaccagacatcactttcaa B830009P17 
Klf3 ggttctccttcctctctgaa tttgatcccagtgtgttttc 1810073A04 
Klf9 cgtttgcagtcgaataaact agatgggaggattttccata 4632425M20 
ler2 gtctacctctcagccaaggt gagagttcgaccctgagatt 6720401C09 
Lrrc20 ggtcaatgagactgtggaaa ctaggctctagcctcacctc A830036L06 
Ltbp1 tggcaaagacagagacaact gttatgaggaaggggacaac C730041O04 
Lum cttggcattagtcggtagtg gataaacgcaggtattgcag 1500035A23 
Lypd6 aatcgtcttgcattctctca ttgctgtgattgtgttgtgt E130115E03 
Maml3 tttattgatccagagccaga gtgtcttagggcaggtcttt C230025H14 
Med30 acttaccaagaccggctaac gcctttgaaaagggtaacag I730042E14 
Meis1 tgcaaacttgacctgtttct accacccctaactccaaata 6720477P20 
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Mgmt cataaacctcaggcctttct agcctggatctatttggaag G630095K06 
Mnd1 gcatgtcaaagaaaagagga catattcacaagctcccaga 2610034E18 
Mrg1 agcaaatcacatggtctcac gccattgcacatattcatct B130038I01 
Mrpl23 Linearized plasmid Linearized plasmid E030002D02 
Msi2 cctcaccagatagccttagag aggggaacagacaggtacag 6030413L18 
Myl4 gagcctaagaaggagactgc gaagccatgtgagtccaata 2810417B17 
Ncor2 ctcaccaagtgtcctctctg tggggtcttcttattcttc F630016H22 
Nfe2l3 ctcacgattctgttgagctt agagaatgttcaggctgtga 5430406J03 
Npvf ggtgacggaaaatactcccagctg accacaggtcacggctccgta Limb cDNA 
Olfr91 tgcttcaccacaacctgtgt tcaaagcctttttccatgct Limb cDNA 
Osr1 acagcaacaaaatcccttg ataaagtgccagtcgcaata 1110067L16 
Osr2 ctgcagctcaccaattactc acagaatcctttcccacact D230050P11 
Pam tcatccactgggagttactg gccacattctgtgtacaggt D130061M01 
Pax1 acattcagtcagcaacatcc ccgaactaggaaggttagga 5830427P13 
Pax9 actcatatcccagtcccatc tcctggaaaagggaagttac 9430070E09 
Pbx1 atgctttaaactgccacaga aaaatttaaatgccctcctg B130052B10 
Pdlim3 tgaaccacaggaattcaaac tgttcttgtctgcaaaggat 6720456D19 
Pmch catccaatgcactcttgttt taatgcacacgtcaagcata A230109K23 
Polr2k Linearized plasmid Linearized plasmid 2010016L13 
Popdc3 atcagagtgacagtcgatgg tgtggaccataatagcaacc D330028H18 
Ppp1r2 tgaatcagtgagaccctgtc gagagaggccaatttcagat E130119E11 
Ppp2r4 caaacttgatcaggaagcag acagcctctcatcaaacaga 6030457C15 
Prdm1 cctgcagaaacactacttgg taccctaagaagcaacacga 5031440G22 
Prkce cgaccatggtagtgttcaat ccaactgtaaggctgttttg A730046G04 
Prokr2 catccatccaggtcactaga atcacatccacaccatgact B830005M06 
Ptch1 Linearized plasmid Linearized plasmid Lab plasmid 
Ptch2 cacacttggaccagctaaag tccttgtatacctgcaccac A730013M03 
Punc tgatcacatgggagaagaac agaaatgctcagtgtgctgt D030056K15 
Pus7I gttgtaaaaccaaaccgtga gcctccaaaattctctctgt 4732482O11 
Ralgps2 ggcttttgaaaggaacagat catctcacttcattccctga 9930012L10 
Ramp2 Linearized plasmid Linearized plasmid 1110019C20 
Rasgef1b gaagcccttatccaacactt gagatgattgccatcaaaga 4732452O09 
Rg9mtd1 ttggcaaagaagtaccagaa gaaggcactctgttgctatg 1300018J16 
Rgs19 agaaggcgcgacttatctat tgcacactgtaggtgtggta A730001O09 
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Rspo3 gcatgaagcagataggagtg tctggttgagatagcagcat 4732402G11 
Rspo4 cagaggctcttcctcttcat gaaaagggagacggataaaa A930029K19 
Runx3 aacccaaatcaatgtcctct ttggttcaaagttgtctgct E130320J01 
Sall1 cttcacttttccgacacttg aacagaacctggagagaagg G630023L11 
Sall3 cctcagctcccagtaagtct tgtttgttacccgcataatc B130022O04 
Sall4 accagtccaagaaaggaaag ccgatgacaaatgagacact C330011P20 
Sap30 actgctgaagtctccatgtg tggtacaaatcaacctctgg E430025B08 
Scube1 tccaatgagggtatgaactg tcatctccacacagtccttc A630023E24 
Sdk2 tgccttctgcaaagttagaa tacctgtactccagcgagaa 5330435L01 
Sfrp2 tatctggtcatgggacagaa gagcaacgaaatgtttgaag I920164A09 
Shcbp1 ccacgaattatccaaacaaa ggatatgtggctcagtggta D930001E18 
Shroom3 cttggctctgtgtctctcac tgaggagtgtggacttcatc 1110002N03 
Slc24a6 ggagatgccttctcagattt gtcaactcgacctctttcct 4632424F05 
Slc26a11 ggtgtccttctacaccttcc ttagcatcaatgcggtagtt F630021I08 
Slc2a1 cttatgggcttctccaaact gctcgctctacaacaaacag F730013E15 
Slc35c1 cctcaatgccatctatacca gtagggctttcccaagacta E430007K15 
Smad7 gaagagagtctccgaggaag gagtagacttcacccctcgt 2810433N14 
Smo caagaagagcaagatgatcg agcctccattaggttagtgc B930075H04 
Smoc1 ctgtgtttgtcccagagtgt attccatcttcttcccttca A530047A09 
Smug1 tccctataaggcctttgaac ccaccaatgaagtgtaggaa 1200013B09 
Sox4 ctgcaggcttcttaaagtga ttttgtggccttgaatttta D130055G04 
Sp1 gtaggcagcagctttcagta aacctatccccaacctaaca E430018D04 
Sparcl1 accactccaacccaactact attgctctctgtttccttcc 6330500I21 
Srp19 cgaccaggacaggtttattt tttcaagtaactcatgggaca 1110036A13 
Stxbp6 cacataatgctttcgcctac aaacctccaaaacccagata K430308H17 
Sulf1 aattcaagctcccagaactc gcctatggggatacattctc B130018L10 
Svep1 tcctgtatcccagttgtttg gacagacacctccattctga 4833413O10 
Tank caggctgaaatcacagctac gaagttatggggtcaattcc E430026L09 
Tbx2 aacatttctgacaagcatgg tgaaacaaaacggaagaaga A930005K01 
Tbx3 ttaaagtgaggtgctctgga cacagatctttgaggttgga D430026F23 
Tbx4 tatcatcctcaactccatgc acgtccacatgttacagctc 3930401C23 
Tcte3 aaaggaagcctagcatgttc ctggtcctgagctattcaca 1700026A18 
Thap1 aacggacagggtagtcactc cgacgtccttctctctctg 4833431A01 
Thap11 ctgcacttctacacgtttcc tcatcttcacttccatcagg G730039J03 
Tmem30b gtgacacatcttgccatttt cccactaagatcatttgcag 9130011B11 
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Tmem48 gcactggaactgagagctta aaacactccctcgaaatagc 2810475A17 
Tmem5 gaacgcattacagcttcatc gtaactgcagaggagcactg 6330415D21 
Tmepai tggtgatggtggttatgatt tctccttctccttgttctcc 2210418I02 
Tmtc1 cttcaatgtatggcttctgc tgaataggcatcagcaaaat B230379O03 
Tpcn1 tcaggagaagatggctgtaa taaagaagagcagcaacagg 5730403B01 
Tpd52l1 gaatcgctaccatctgctg agtgggattttggtcttcat 1810073J04 
Trim59 tcaggagattgacagaccag ttcattccttgaatctgtgg 4933403N21 
Trim62 gggacagaggtcctacaatc atggacatgctcactgaatc 1110038I18 
Trp53rk tctttgtggactatgcgtct ggatgttgccataaattcaa C330019P15 
Ube2t cttgagatcatgcagagagc caaaagagaccaccttgaca C330020M11 
Ust gagacatgtccacttcctca catttttcgtcatcttgctc D930010O20 
Whrn gtactacctggcccagtacc tcagaggacaacttgcactt F930011M09 
Wnt11 ctgcatgaagaatgagaagg aaagagggattgaagtgagc 5930404H12 
Xpa gaggaaaagcagacgtcac cccctctccttacctacaga 2210417B19 
Xpnpep2 aacagatggagacctggaat aggctaaagcgactcttgtt 9030008G12 
Zfp281 ttactcaccaccttcacgtc ttatacatggaagcctgtgg 9330157H23 
Zfp64 gtggaaggagacaccttttc atgaaacctggcttttgttt 2700078A12 
Zfp704 cttgtgccaaaacagacact ttggctaagctgctacagaa 6820415O14 
Zic3 aacaaccacgtctgctattg accagcatcttcccatttat 9430037B07 
Zmiz1 agtacaggctgtgtgtcagg gactgtgttctgggagtgaa E330020C23 
Ube2v1  Linearized plasmid  Linearized plasmid Lab plasmid 
Table C1, cont.  
 
C.4: QUANTITATIVE REVERSE-TRANSCRIPTASE PCR  
RNA was extracted using TRIzol (Invitrogen). 300ng of DNAse I treated RNA was 
used to synthesize cDNA using random hexamers and SuperScript II (Invitrogen). qRT-
PCR experiments were performed using SensiFast SYBR lo-rox (Bioline) on a Viia7 
platform (Applied Biosystems).  
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C.5: SHH-/- FORELIMB RNASEQ 
To generate Shh-/- embryos, heterozygous Shhtm1Amc mice (in previous generations 
mated to a Cre deleter strain to generate a null allele) (Dassule et al., 2000) were crossed, 
and E10.25 (33 to 35 somites) embryos were collected and genotyped for the wild-type and 
null allele. Forelimbs were collected and combined from three embryos of the same 
genotype, and RNA was isolated using TRIzol (Invitrogen) and treated with DNase I. Two 
biological replicates for each genotype were sequenced. The average Shh-/- somite number 
for replicate one was 34, and replicate two was  
33.3. The average wild-type somite number for replicate one was 34, and replicate two was 
33.7. Library construction was performed following Illumina manufacturer suggestions, 
and libraries were sequenced on the Illumina HiSeq platform using paired-end sequencing. 
Reads were aligned to the mouse reference genome mm10 using TopHat 2.0.9 (Trapnell et 
al., 2009) with default parameters and the option to incorporate genome annotation 
(parameter “-G”). Aligned reads were assigned to genes by HTSeq-count  (Anders et al., 
2010) using the default unioncounting mode. Following HTSeq-count, edgeR 3.4.2 was 
used to conduct differential expression analysis (‘classic’ edgeR) (Robinson et al., 2010). 
Differentially expressed genes were identified based on an FDR of 0.05 and a mean fold 
change of 25% (supplementary material Table S3).  The data discussed in this publication 
have been deposited in NCBI’s Gene Expression Omnibus and are accessible through GEO 
Series accession number GSE58222.  
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C.6: CYCLOPAMINE TREATED WILD-TYPE FORELIMB RNASEQ 
Wild-type E10.25 (31-34 somites) forelimbs were cultured as described in (Panman 
et al., 2006; Zúñiga et al., 1999). For each culture condition, forelimb pairs from seven 
wild-type embryos were cultured for 15 hours in 10 µM cyclopamine (Toronto Research) 
or in 0.125% ethanol for controls. Immediately after the incubation period, limb buds were 
separated from the adjacent tissue and RNA was isolated using TRIzol (Invitrogen) and 
treated with DNase I. Two biological replicates for each culture condition were sequenced. 
The average somite number for wild-type controls was 32 for replicate one, and 32.6 for 
replicate two. The average somite number for wild-type samples treated with cyclopamine 
was 32 for replicate one, and 32.8 for replicate two. Library preparations were generated 
following ABI manufacturer suggestions, and libraries were sequenced on an ABI SOLiD 
platform using paired-end sequencing. Reads were aligned to the mouse reference genome 
mm10 using TopHat 2.0.9 (Trapnell et al., 2009) with default parameters and the option to 
incorporate genome annotation (parameter “-G”). Aligned reads were assigned to genes by 
HTSeq-count (Anders et al., 2010) using the default union-counting mode. Following 
HTSeq-count, edgeR 3.4.2 was used to conduct differential expression analysis (‘classic’ 
edgeR) (Robinson et al., 2010).  Differentially expressed genes were identified based on an 
FDR of 0.05 and a mean fold change of 25% (supplementary material Table S4). The data 
discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus 
and are accessible through GEO series accession number GSE58222. 
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C.7: DE NOVO MOTIF DISCOVERY AND GLI MOTIF QUALITY ANALYSIS 
De novo motif discovery was performed DNA motifs in GLI-bound CRMs were 
discovered by de novo motif discovery method. We mapped motif PWMs to GLI-bound 
CRMs in each category, background sequences were modeled as a third-order Markov 
chain (Ji et al. 2006). Then, we compared relative enrichment levels (r1) of the discovered 
motifs in high-quality binding regions versus matched control genomic regions. We chose 
a motif selection procedure to select enriched motifs by simultaneously requiring r1>= 2, 
number of motif sites (n1B) >= max(1/5*(number of genes),5), motif score >= 1. We used 
TOMTOM motif comparison tool to visualize their sequence logos with their PWMs as 
input. The quality of Gli motifs was assessed by using a Gli motif with the highest score, 
and then mapped the PWM of the Gli motif to GLI-bound CRMs within each category. 
The Gli matrix was compared to a third-order background Markov model. A log-likelihood 
ratio for Gli motif quality was determined as described previously (Vokes et al., 2007). 
With the Gli consensus-binding pattern from each binding region, we calculated probability 
for each motif site in each category using a Welch’s t-test.   
 
C.8: SP1 MOTIF META-ANALYSIS 
The peak lists were from hmChIP publically available mouse TF ChIP datasets and 
analyzed using CisGenome software. Here we had two controls for each peak list: matched 
genomic controls and random controls. For each control, we compared relative enrichment 
(r1) of Sp1 motif.  r1>2 means Sp1 is enriched, while r1<1 means sp1 is not enriched. 
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Additional ChIP datasets were obtained from (Cotney et al., 2012; DeMare et al., 2013; 
Infante et al., 2013; Peterson et al., 2012; Visel et al., 2009). For each peak list from the 
papers, we overlapped the GLI3 peaks with all the peaks in the limb bud and divided it into 
two datasets: regions containing Gli3 and regions without Gli3. The Sp1 enrichment 
analyses were the same as peak lists from hmChIP.   
 
C.9: CO-IMMUNOPRECIPITATION  
Female RosaGli1-Flagc/c (Vokes et al., 2007) were mated to male Prx1Cre mice 
(Logan et al., 2002), and embryo forelimbs were collected at E10.5. Protein lysate was run 
on a 10% SDSPAGE gel, and assayed for SP1 (Millipore 07645, 1:1000) and M2 anti-
FLAG (Sigma, 1:2000).    
 
C.10: MOUSE FORELIMB TRUNK CULTURES 
Embryo trunks containing forelimbs were cultured as previously described 
(Panman et al., 2006; Aimee Zuniga et al., 1999). To inhibit HH signaling, limb buds were 
cultured for 15 hours in 10 μM cyclopamine (Toronto Research) or in 0.125% ethanol for 
controls. To inhibit SP-mediated transcription, contralateral forelimbs were cultured for 15 
h in 300 nM mithramycin A (Sigma) or 0.03% DMSO for controls.  To inhibit FGF 
signaling, contralateral forelimbs were cultured for 4, 8, and 15 hours in media containing 
10 μM SU5402 (Tocris) or 0.125% DMSO for controls.  To activate the SHH pathway, 
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contralateral forelimbs were cultured for 15 hours in 10 μM purmorphamine (Stemgent) or 
0.125% DMSO. Immediately after incubation, limb buds were processed for in situ 
hybridization, β-galactosidase staining (Whiting et al., 1991), or separated from the 
adjacent tissue and processed for qRT-PCR.   
 
C11: DISSECTING, DISSOCIATING, AND NUCLEOFECTING MOUSE LIMB CELLS 
1. Dissect forelimbs at the proximal base, excluding the adjacent mesoderm from 
E10.25-E10.5 (33-36 somites) mouse embryos. Note that the ectoderm is not 
specifically removed. Place dissected forelimbs in a petri dish containing PBS and 
keep on ice.  Limb buds from multiple litters can be pooled.  
2. Transfer limb buds to a 15ml tube and pulse centrifuge, and remove the PBS 
supernatant. 
3. Add 1 mL of 0.25% Trypsin/EDTA to the 15mL tube, and incubate at 37oC for 10 
min.   
4. Gently pipette the limb buds with a P1000 tip to further dissociated until there are 
minimal clumps of tissue. 
5. Inactivate the Trypsin by adding 9mL of limb bud culture media (10% calf serum) 
to the 15 mL tube.   
6. Remove the remaining tissue aggregates with a 40 µm cell strainer.  Place the nylon 
filter on top of a 50 mL tube and apply the 10 mL cell mixture.  Save the cell flow-
through.   
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7. Determine the concentration of cells in the flow-through using a hemocytometer. 
8. Determine the number of electroporations and transfer the appropriate volume of 
cells to a single 15 mL tube and centrifuge at 200 x g for 5 min. One electroporation 
requires 7.5x105 cells. 
9. While the cells are centrifuging, prepare the complete electroporation solution by 
combining the appropriate volume of SF solution and Supplemental 1 solution into 
a 1.5 mL tube, and incubate at 37oC.  A single electroporation requires 18 µL SF 
solution and 4 µL Supplemental 1 solution (complete electroporation solution). 
10. Remove all of the cell culture media and add the total volume of the complete 
electroporation solution to a 15 mL conical tube.  Using a P1000 pipette, gently 
suspend the cells in the solution, and transfer to a new 1.5 mL tube. 
11. For each electroporation transfer 20 µL of cells into a new 1.5 mL tube, and add 
1-4 µL of prepared DNA / RNA.   
12. Pipette mixture 1-2 times and transfer the entire mixture to an electroporation 
cuvette.  
13. Electroporate the sample(s) using the 96-well Shuttle System (Lonza AAM-
1001S) set to program DS113.  
14. After electroporation, add 80 µL of pre-warmed (37C) limb cell culture media 
(high serum) to each electroporation cuvette, and incubate at 37C for 10 min.    
15. While the cells are recovering prepare the 96-well half area plate with the 
appropriate cell culture media.   Add 20 µL of either FGF8 concentrate media 
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(750 ng/mL) or FGF8 (750 ng/mL) and purmorphamine (25 µM) concentrate 
media to each well.    
16. Remove the electroporation cuvette plate from the 37oC incubator and transfer 
(~100 µl) of the electroporated cells to a new 1.5 mL tube.   Wash each cuvette 
with 100µl of limb cell culture media (high serum) to each well and transfer the 
wash media to the corresponding 1.5 mL tube.   The total volume of the 1.5 mL 
tube is ~200 µl. 
17. Add 80 µl of electroporated cells to each well containing 20 µL of concentrated 
media on the 96-well half-area plate. The final volume in each well is 100 µL; the 
final concentrations of FGF8 and purmorphamine are 150 ng/mL and 5 µM, 
respectively.  
18. Every 24 hours change the media or perform assay (luciferase, qRT-PCR). 
19. For qRT-PCR experiments, carefully remove the media, and add 100 µL of 
Trypsin/EDTA, and incubate at 37oC for 5 min.  Transfer the cells into a 1.5 mL 
tube and wash the well out with 100 µL PBS and add to the same tube.   
Centrifuge the 1.5 mL tubes containing the cells at 350 x g, remove the 
supernatant and proceed to RNA isolation (see RNA isolation and qRT-PCR 
section for the complete methods). 
20. For Gaussia luciferase experiments, replace the media with limb bud cell media 
containing 0.5% serum 24 hours post electroporation. 
 129 
C12: GAUSSIA LUCIFERASE ASSAY 
To determine if this method could be used to assay the activity of DNA regulatory 
elements, we electroporated 300ng of a Hh responsive element, the Drosophila Patched 
promoter, upstream of the Gaussia luciferase reporter gene (Pastrana et al., 2009), and 
100ng of a LacZ plasmid (pSV40LacZ). Gaussia -
-Galactosidase Assay Kit (Novagen, #70979).  
 
C13: FLOW CYTOMETRY ANALYSIS 
Limb bud cells were electroporated with 1µg of GFPmax plasmid (Lonza) or 10 
picomoles of Cy3-labeled Gapdh siRNA, and cultured for 24 hours.  To determine the 
electroporation efficiencies flow cytometry analysis was performed using a LSR Fortessa 
(BD Biosciences), and the primary data were processed using FlowJo software (Tree Star). 
 
C14: ALCIAN BLUE STAINING AND IMAGING  
To determine if cells were adopting a chondrogenic fate, limb cells in culture were 
stained with Alcian blue at 72 hours as previously described (Paulsen and Solursh, 1988). 
Briefly, cells were washed 2x with 150µL PBS, and then cells were fixed with 150µL of 
acidified alcohol for 15 min.  Cells were rehydrated sequentially in 150 µL 95%, 80%, 
70%, 50%, 25% ethanol for 5 min.   Ethanol was removed and 150 µL of Alcian blue stain 
was added and incubated at 4oC for 16 hours.   Cells were washed 8x with 150 µL 0.1N 
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HCl with agitation, and washed 1x with 150 µL H2O.   All liquid was removed, and cells 
were imaged on a Leica M165 FC stereomicroscope. 
C15: GRE1 MOUSE TRANSGENICS 
The GRE1LacZ transgenic line, officially named Tg(Rr26-lacZ)438Svok 
(MGI:5052053), was generated by pronuclear injection using the previously described 
enhancer reporter construct containing the 438-bp Gli binding region (chr2:113640843-
113641280) (Vokes et al., 2008). The BAC transgenic constructs were generated using the 
Quick&Easy BAC Modification Kit (Gene Bridges) to modify a previously generated BAC 
containing LacZ within the Gremlin transcript (Zuniga et al., 2004). The homology arms 
for both targeting vectors were chr2:113,640,295-113,640,842 and chr2:113,641,281-
113,641,757. After targeting, the FRT-flanked neomycin-resistance cassette was removed 
with a heat shock inducible FlpE construct (Gene Bridges), leaving a 69-bp FRT site and 
linker sequence precisely in place of the Gli CRM (chr2113640843-113641280). The 
official name for the Gremlin∆GRE1 allele is Rr26<tm1Svok> (MGI:5486166). This allele 
results in the replacement of the 438-bp CRM sequence with an 89-bp sequence containing 
a single LoxP scar. Further details on the generation of this allele are provided in the 
supplemental information (Fig. S4). 
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C16: PRIMERS  
 
Gene name Forward Primer Reverse Primer 
Adamts19 aagccggcacatagcttctt cagccagactgaatgctcca 
Agc1 ggtcactgttaccgccactt ccccttcgatagtcctgtca 
Axin2 gaggagatcgaggcagaagc cacctctgctgccacaaaac 
B-Actin gctgtattcccctccatcgtg cacggttggccttagggttcag 
Calml4 ttctggtgtccatgaggtgc gaagtccagctctccgttct 
Cdk6 tcccaggagaggaagactgg gccgtaggcggatatccttt 
Cntfr tgtttccaccgtgactcctg agctgcagtagaagcccttg 
Dock6 cagccccgagaatgccggac ggaggtgaggcctttctgcc 
Dusp6 cggaaatggcgatctgcaag gacgactcgtacagctcctg 
Fam181b tcggaagtctggacaaaggc acgccgagtctatgaagctg 
Fbxo41 atgtgggctcccgaactact gaggatttctgggctgatga 
Fbxo8 tccggcaacaataggaaacgtc ttcgcgctggagaacacgat 
Fgf8 ccggacctaccagctctaca ggcaattagcttccccttct 
Fmn1 gacgccgcaccaactttatg ggcctctgacaggggttttt 
Gapdh ggtgaaggtcggtgtgaacg ctcgctcctggaagatggtg 
Gli1 cccagctcgctccgcaaaca ctgctgcggcatggcactct 
Grem1 actcgtccacagcgaagaac tcattgtgctgagccttgtc 
Hand2 ccataatgggagtggtccag cgaggagaacccctacttcc 
Hhip gctccctgctccccgcattc acctggaatatggcctcggca 
HoxD13 tgtccacttttggatccgg ttcttccttccccgtcggta 
Ier2 aagaggaagtgctgcgagtc tagacgggccttcttgcttg 
Jag1 gtgctacaatcgtgccagtg ggggaccacagacgttagaa 
Klf9 tctggagagtcccgatgagg gaaagggccgttcacctgta 
LacZ gggccgcaagaaaactatcc tctgacaatggcagatccca 
Ltbp1 agctttgccagatccctgtc ctttgaccccttgctggcta 
Msi2 acgattgacccaaaagttgc catcagcatcgcatcctcta 
Msx2 caagtgaagggggaggtgta cagggacctgacatggagtt 
Ndnf agcgcacactccttgcc gtggcgggaggatactgaac 
Osr1 gaggggctttcgggatcttc tttggccaagttttagccgc 
Osr2 ccttccagccctacacaagg gcttgctcaggtctcccatt 
Pam gggactgtgtacattggcga aactgcctcggcttctttga 
Table C2: Primers used in qRT-PCR experiments. 
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Prdm1 atccagcttccctaccgagt gggggactactctcgtcctt 
Ptch1 gaccggccttgcctcaaccc cagggcgtgagcgctgacaa 
Ralgps2 aggctcaggggctgatgagga cgcgtattcttctggcgtaacct 
Rasgef1b gcagcagtgaccaaatgcaa caacatggctggaacttggc 
Rpso3 atggggtgctcctagccc taccgcagccatggtcaag 
Sall1 gcctaccattgcctccaact cgccacttgggtttcttgtg 
Sall3 catgtggaacaatgcacccg atgcctccgttctggatgac 
Sap30 ttcaagcttccaaccagacc gccttgagatccgatttgtt 
Shh tctcgagacccaactccgat gacttgtctccgatccccac 
Smoc1 tgctcacgccccacttgctg agggctgggtctcggcactt 
Sox4 ggagatgtgctgggagtagc ctgggtagcctcacctctct 
Sox9 taagttccccgtgtgcatcc ttgcccagagtcttgctgag 
Sp1 tgctgcttcgagtctgagaa agcgaccaagatcactccat 
Sp3 ctcgctctgctggccgctac cccatcggtttggtgctcctcc 
Spry4 gacccactcgggttcgggga ggggcgctctgctgtcaagg 
Svep1 tgtcctgacgtaagccacac ggcggcattgaagtggtttt 
Tbp ggcctctcagaagcatcacta gccaagccctgagcataa 
Tpd52l1 aatcgctaccatctgctgct cttccttgtagcggttccgt 
Table C2, cont.  
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Commonly used abbreviations  
 
Shh  Sonic hedgehog 
Hh  Hedgehog 
Fgf  Fibroblast Growth Factor 
GRE1  Gremlin regulatory element 1 
CRM  Cis-regulatory module 
KD  Knockdown 
siRNA  Small interfering RNA 
PM  Purmorphamine  
MitA  Mithramycin A 
Cyc  Cyclopamine 
FDR  False Discovery Rate 
FC  Fold change 
qRT-PCR Quantitative Reverse Transcriptase PCR  
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